ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT

Tecentriq 840 mg concentrate for solution for infusion
Tecentriq 1 200 mg concentrate for solution for infusion

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Tecentriq 840 mg concentrate for solution for infusion
One 14 mL vial of concentrate contains 840 mg of atezolizumab*

Tecentriq 1 200 mg concentrate for solution for infusion
One 20 mL vial of concentrate contains 1 200 mg atezolizumab*

After dilution (see section 6.6), the final concentration of the diluted solution should be between 3.2 and 16.8 mg/mL.

*Atezolizumab is an Fc-engineered, humanised IgG1 anti-programmed death-ligand 1 (PD-L1) monoclonal antibody produced in Chinese hamster ovary cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Concentrate for solution for infusion.
Clear, colourless to slightly yellowish liquid.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Urothelial carcinoma (UC)

Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic UC:

- after prior platinum-containing chemotherapy, or
- who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).

Early-stage non-small cell lung cancer (NSCLC)

Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1 for selection criteria).

Metastatic NSCLC

Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1).
Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).

Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumours have a PD-L1 expression ≥ 50% TC or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).

Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).

Small cell lung cancer (SCLC)

Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see section 5.1).

Triple-negative breast cancer (TNBC)

Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Hepatocellular carcinoma (HCC)

Tecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable HCC who have not received prior systemic therapy (see section 5.1).

4.2 Posology and method of administration

Tecentriq must be initiated and supervised by physicians experienced in the treatment of cancer.

PD-L1 testing for patients with UC or TNBC or NSCLC

Tecentriq monotherapy

Patients with first-line (1L) UC, early-stage NSCLC, and 1L metastatic NSCLC should be selected for treatment based on the tumour expression of PD-L1 confirmed by a validated test (see section 5.1).

Tecentriq in combination therapy

Patients with previously untreated TNBC should be selected for treatment based on the tumour expression of PD-L1 confirmed by a validated test (see section 5.1).

Posology

The recommended dose of Tecentriq is either 840 mg administered intravenously every two weeks, or 1 200 mg administered intravenously every three weeks, or 1 680 mg administered intravenously every four weeks, as presented in Table 1.

When Tecentriq is administered in combination therapy please also refer to the full prescribing information for the combination products (see also section 5.1).
Table 1: Recommended dose for Tecentriq by intravenous administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Recommended dose and schedule</th>
<th>Duration of treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tecentriq monotherapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1L UC</td>
<td>• 840 mg every 2 weeks or • 1 200 mg every 3 weeks or • 1 680 mg every 4 weeks</td>
<td>Until disease progression or unmanageable toxicity</td>
</tr>
<tr>
<td>1L metastatic NSCLC</td>
<td>• 840 mg every 2 weeks or • 1 200 mg every 3 weeks or • 1 680 mg every 4 weeks</td>
<td>For 1 year unless disease recurrence or unacceptable toxicity. Treatment duration for more than 1 year was not studied.</td>
</tr>
<tr>
<td>Early-stage NSCLC</td>
<td>• 840 mg every 2 weeks or • 1 200 mg every 3 weeks or • 1 680 mg every 4 weeks</td>
<td>Until loss of clinical benefit or unmanageable toxicity</td>
</tr>
<tr>
<td>2L UC</td>
<td>• 840 mg every 2 weeks or • 1 200 mg every 3 weeks or • 1 680 mg every 4 weeks</td>
<td>Until disease progression or unmanageable toxicity</td>
</tr>
<tr>
<td>2L NSCLC</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tecentriq combination therapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1L non-squamous NSCLC with bevacizumab, paclitaxel, and carboplatin</td>
<td>Induction and maintenance phases: • 840 mg every 2 weeks or • 1 200 mg every 3 weeks or • 1 680 mg every 4 weeks Tecentriq should be administered first when given on the same day. Induction phase for combination partners (four or six cycles): Bevacizumab, paclitaxel, and then carboplatin are administered every three weeks. Maintenance phase (without chemotherapy): Bevacizumab every 3 weeks.</td>
<td>Until disease progression or unmanageable toxicity. Atypical responses (i.e., an initial disease progression followed by tumour shrinkage) have been observed with continued Tecentriq treatment after disease progression. Treatment beyond disease progression may be considered at the discretion of the physician.</td>
</tr>
<tr>
<td>1L non-squamous NSCLC with nab-paclitaxel and carboplatin</td>
<td>Induction and maintenance phases: • 840 mg every 2 weeks or • 1 200 mg every 3 weeks or • 1 680 mg every 4 weeks Tecentriq should be administered first when given on the same day. Induction phase for combination partners (four or six cycles): Nab-paclitaxel, and carboplatin are administered on day 1; in addition, nab-paclitaxel is administered on days 8 and 15 of each 3-weekly cycle.</td>
<td>Until disease progression or unmanageable toxicity. Atypical responses (i.e., an initial disease progression followed by tumour shrinkage) have been observed with continued Tecentriq treatment after disease progression. Treatment beyond disease progression may be considered at the discretion of the physician.</td>
</tr>
<tr>
<td>Indication</td>
<td>Recommended dose and schedule</td>
<td>Duration of treatment</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------</td>
<td>-----------------------</td>
</tr>
</tbody>
</table>
| 1L ES-SCLC with carboplatin and etoposide | Induction and maintenance phases:  
- 840 mg every 2 weeks or  
- 1 200 mg every 3 weeks or  
- 1 680 mg every 4 weeks
Tecentriq should be administered first when given on the same day.  
Induction phase for combination partners (four cycles): Carboplatin, and then etoposide are administered on day 1; etoposide is also administered on days 2 and 3 of each 3-weekly cycle. | Until disease progression or unmanageable toxicity. Atypical responses (i.e., an initial disease progression followed by tumour shrinkage) have been observed with continued Tecentriq treatment after disease progression. Treatment beyond disease progression may be considered at the discretion of the physician. |
| 1L unresectable locally advanced or metastatic TNBC with nab-paclitaxel | • 840 mg every 2 weeks or  
• 1 200 mg every 3 weeks or  
• 1 680 mg every 4 weeks
Tecentriq should be administered prior to nab-paclitaxel when given on the same day. Nab-paclitaxel should be administered at 100 mg/ m² on days 1, 8, and 15 of each 28-day cycle. | Until disease progression or unmanageable toxicity. |
| Advanced or unresectable HCC with bevacizumab | • 840 mg every 2 weeks or  
• 1 200 mg every 3 weeks or  
• 1 680 mg every 4 weeks
Tecentriq should be administered prior to bevacizumab when given on the same day. Bevacizumab is administered at 15 mg/kg body weight (bw) every 3 weeks. | Until loss of clinical benefit or unmanageable toxicity. |

**Delayed or missed doses**

If a planned dose of Tecentriq is missed, it should be administered as soon as possible. The schedule of administration must be adjusted to maintain the appropriate interval between doses.

**Dose modifications during treatment**

Dose reductions of Tecentriq are not recommended.
Dose delay or discontinuation (see also sections 4.4 and 4.8)

Table 2: Dose modification advice for Tecentriq

<table>
<thead>
<tr>
<th>Immune-mediated adverse reaction</th>
<th>Severity</th>
<th>Treatment modification</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pneumonitis</strong></td>
<td>Grade 2</td>
<td>Withhold Tecentriq</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Grade 3 or 4</td>
<td>Permanently discontinue Tecentriq</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatitis in patients without HCC</strong></td>
<td>Grade 2: (ALT or AST &gt; 3 to 5 x upper limit of normal [ULN]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>or</td>
</tr>
<tr>
<td></td>
<td></td>
<td>blood bilirubin &gt; 1.5 to 3 x ULN)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Grade 3 or 4: (ALT or AST &gt; 5 x ULN</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>or</td>
</tr>
<tr>
<td></td>
<td></td>
<td>blood bilirubin &gt; 3 x ULN)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Withhold Tecentriq</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treatment may be resumed when the event improves to Grade 0 or Grade 1 within 12 weeks and corticosteroids have been reduced to ≤ 10 mg prednisone or equivalent per day</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Permanently discontinue Tecentriq</td>
</tr>
<tr>
<td>Immune-mediated adverse reaction</td>
<td>Severity</td>
<td>Treatment modification</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>----------</td>
<td>------------------------</td>
</tr>
</tbody>
</table>
| **Hepatitis in patients with HCC** | If AST/ALT is within normal limits at baseline and increases to $> 3 \times$ to $\leq 10 \times$ ULN  
  or  
  If AST/ALT is $> 1 \times$ to $\leq 3 \times$ ULN at baseline and increases to $> 5 \times$ to $\leq 10 \times$ ULN  
  or  
  If AST/ALT is $> 3 \times$ to $\leq 5 \times$ ULN at baseline and increases to $> 8 \times$ to $\leq 10 \times$ ULN  
  or  
  If AST/ALT increases to $> 10 \times$ ULN  
  or  
  total bilirubin increases to $> 3 \times$ ULN | Withhold Tecentriq  
 Treatment may be resumed when the event improves to Grade 0 or Grade 1 within 12 weeks and corticosteroids have been reduced to $\leq 10$ mg prednisone or equivalent per day  
 Permanently discontinue Tecentriq |
| **Colitis** | Grade 2 or 3 Diarrhoea (increase of $\geq 4$ stools/day over baseline)  
  or  
  Symptomatic Colitis | Withhold Tecentriq  
 Treatment may be resumed when the event improves to Grade 0 or Grade 1 within 12 weeks and corticosteroids have been reduced to $\leq 10$ mg prednisone or equivalent per day  
 Permanently discontinue Tecentriq |
| **Hypothyroidism or hyperthyroidism** | Symptomatic | Withhold Tecentriq  
 *Hypothyroidism*:  
 Treatment may be resumed when symptoms are controlled by thyroid replacement therapy and TSH levels are decreasing  
 *Hyperthyroidism*:  
 Treatment may be resumed when symptoms are controlled by anti-thyroid medicinal product and thyroid function is improving |
| **Adrenal insufficiency** | Symptomatic | Withhold Tecentriq  
 Treatment may be resumed when the symptoms improve to Grade 0 or Grade 1 within 12 weeks and corticosteroids have been reduced to $\leq 10$ mg prednisone or equivalent per day and patient is stable on replacement therapy |
<table>
<thead>
<tr>
<th>Immune-mediated adverse reaction</th>
<th>Severity</th>
<th>Treatment modification</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hypophysitis</strong></td>
<td>Grade 2 or 3</td>
<td>Withhold Tecentriq</td>
</tr>
<tr>
<td></td>
<td>Grade 4</td>
<td>Permanently discontinue Tecentriq</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treatment may be resumed when the symptoms improve to Grade 0 or Grade 1 within 12 weeks and corticosteroids have been reduced to ≤ 10 mg prednisone or equivalent per day and patient is stable on replacement therapy</td>
</tr>
<tr>
<td><strong>Type 1 diabetes mellitus</strong></td>
<td>Grade 3 or 4 hyperglycaemia (fasting glucose &gt; 250 mg/dL or 13.9 mmol/L)</td>
<td>Withhold Tecentriq</td>
</tr>
<tr>
<td></td>
<td>Grade 4</td>
<td>Permanently discontinue Tecentriq</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treatment may be resumed when metabolic control is achieved on insulin replacement therapy</td>
</tr>
<tr>
<td><strong>Rash/Severe cutaneous adverse reactions</strong></td>
<td>Grade 3</td>
<td>Withhold Tecentriq</td>
</tr>
<tr>
<td></td>
<td>or suspected Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)¹</td>
<td>Treatment may be resumed when the symptoms improve to Grade 0 or Grade 1 within 12 weeks and corticosteroids have been reduced to ≤ 10 mg prednisone or equivalent per day</td>
</tr>
<tr>
<td></td>
<td>Grade 4</td>
<td>Permanently discontinue Tecentriq</td>
</tr>
<tr>
<td></td>
<td>or confirmed Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)¹</td>
<td></td>
</tr>
<tr>
<td><strong>Myasthenic syndrome/myasthenia gravis, Guillain-Barré syndrome, Meningoencephalitis and Facial paresis</strong></td>
<td>Facial paresis Grade 1 or 2</td>
<td>Withhold Tecentriq</td>
</tr>
<tr>
<td></td>
<td>All Grades Myasthenic syndrome/myasthenia gravis, Guillain Barré syndrome and Meningoencephalitis or Facial paresis Grade 3 or 4</td>
<td>Permanently discontinue Tecentriq</td>
</tr>
<tr>
<td><strong>Myelitis</strong></td>
<td>Grade 2, 3, or 4</td>
<td>Permanently discontinue Tecentriq</td>
</tr>
<tr>
<td>Immune-mediated adverse reaction</td>
<td>Severity</td>
<td>Treatment modification</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>----------</td>
<td>------------------------</td>
</tr>
</tbody>
</table>
| **Pancreatitis**                | Grade 3 or 4 serum amylase or lipase levels increased (> 2 x ULN) or Grade 2 or 3 pancreatitis | Withhold Tecentriq  
Treatment may be resumed when serum amylase and lipase levels improve to Grade 0 or Grade 1 within 12 weeks, or symptoms of pancreatitis have resolved, and corticosteroids have been reduced to ≤ 10 mg prednisone or equivalent per day |
|                                 | Grade 4 or any grade of recurrent pancreatitis | Permanently discontinue Tecentriq |
| **Myocarditis**                 | Grade 2 or above | Permanently discontinue Tecentriq |
| **Nephritis**                   | Grade 2: (creatinine level > 1.5 to 3.0 x baseline or > 1.5 to 3.0 x ULN) | Withhold Tecentriq  
Treatment may be resumed when the event improves to Grade 0 or Grade 1 within 12 weeks and corticosteroids have been reduced to ≤ 10 mg prednisone or equivalent per day |
|                                 | Grade 3 or 4: (creatinine level > 3.0 x baseline or > 3.0 x ULN) | Permanently discontinue Tecentriq |
| **Myositis**                    | Grade 2 or 3 | Withhold Tecentriq |
|                                 | Grade 4 or Grade 3 recurrent myositis | Permanently discontinue Tecentriq |
| **Pericardial disorders**       | Grade 1 pericarditis | Withhold Tecentriq  
2 Conduct a detailed cardiac evaluation to determine the etiology and manage appropriately |
|                                 | Grade 2 or above | Permanently discontinue Tecentriq |
| **Haemophagocytic lymphohistiocytosis** | Suspected haemophagocytic lymphohistiocytosis¹ | Permanently discontinue Tecentriq |
| **Other immune-mediated adverse reactions** | Grade 2 or Grade 3 | Withhold until adverse reactions recovers to Grade 0-1 within 12 weeks, and corticosteroids have been reduced to ≤ 10 mg prednisone or equivalent per day |
|                                 | Grade 4 or recurrent Grade 3 | Permanently discontinue Tecentriq (except endocrinopathies controlled with replacement hormones) |
| **Other adverse reactions**     | Severity | Treatment modification |
| **Infusion-related reactions**  | Grade 1 or 2 | Reduce infusion rate or interrupt. Treatment may be resumed when the event is resolved |
|                                 | Grade 3 or 4 | Permanently discontinue Tecentriq |

Note: Toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Event Version 4.0 (NCI-CTCAE v.4.).  
¹ Regardless of severity  
² Conduct a detailed cardiac evaluation to determine the etiology and manage appropriately
**Special populations**

**Paediatric population**

The safety and efficacy of Tecentriq in children and adolescents aged below 18 years have not been established. Currently available data are described in sections 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.

**Elderly**

Based on a population pharmacokinetic analysis, no dose adjustment of Tecentriq is required in patients ≥ 65 years of age (see sections 4.8 and 5.1).

**Asian patients**

Due to increased haematologic toxicities observed in Asian patients in IMpower150, it is recommended that the starting dose of paclitaxel should be 175 mg/m² every three weeks.

**Renal impairment**

Based on a population pharmacokinetic analysis, no dose adjustment is required in patients with mild or moderate renal impairment (see section 5.2). Data from patients with severe renal impairment are too limited to draw conclusions on this population.

**Hepatic impairment**

Based on a population pharmacokinetic analysis, no dose adjustment is required for patients with mild or moderate hepatic impairment. Tecentriq has not been studied in patients with severe hepatic impairment (see section 5.2).

**Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2**

Patients with ECOG performance status ≥ 2 were excluded from the clinical trials in NSCLC, TNBC, ES-SCLC, 2nd line UC and HCC (see sections 4.4 and 5.1).

**Method of administration**

Tecentriq is for intravenous use. The infusions must not be administered as an intravenous push or bolus.

The initial dose of Tecentriq must be administered over 60 minutes. If the first infusion is well tolerated, all subsequent infusions may be administered over 30 minutes.

For instructions on dilution and handling of the medicinal product before administration, see section 6.6.

**4.3 Contraindications**

Hypersensitivity to atezolizumab or to any of the excipients listed in section 6.1.

**4.4 Special warnings and precautions for use**

**Traceability**

In order to improve the traceability of biological medicinal products, the trade name and the batch number of the administered product should be clearly recorded in the patient file.
Immune-mediated adverse reactions

Most immune-mediated adverse reactions occurring during treatment with atezolizumab were reversible with interruptions of atezolizumab and initiation of corticosteroids and/or supportive care. Immune-mediated adverse reactions affecting more than one body system have been observed. Immune-mediated adverse reactions with atezolizumab may occur after the last dose of atezolizumab.

For suspected immune-mediated adverse reactions, thorough evaluation to confirm aetiology or exclude other causes should be performed. Based on the severity of the adverse reaction, atezolizumab should be withheld and corticosteroids administered. Upon improvement to Grade ≤ 1, corticosteroid should be tapered over ≥ 1 month. Based on limited data from clinical trials in patients whose immune-mediated adverse reactions could not be controlled with systemic corticosteroid use, administration of other systemic immunosuppressants may be considered.

Atezolizumab must be permanently discontinued for any Grade 3 immune-mediated adverse reaction that recurs and for any Grade 4 immune-mediated adverse reactions, except for endocrinopathies that are controlled with replacement hormones (see sections 4.2 and 4.8).

Immune-mediated pneumonitis

Cases of pneumonitis, including fatal cases, have been observed in clinical trials with atezolizumab (see section 4.8). Patients should be monitored for signs and symptoms of pneumonitis and causes other than immune-mediated pneumonitis should be ruled out.

Treatment with atezolizumab should be withheld for Grade 2 pneumonitis, and 1 to 2 mg/kg body weight (bw)/day prednisone or equivalent should be started. If symptoms improve to ≤ Grade 1, corticosteroids should be tapered over ≥ 1 month. Treatment with atezolizumab may be resumed if the event improves to ≤ Grade 1 within 12 weeks, and corticosteroids have been reduced to ≤ 10 mg prednisone or equivalent per day. Treatment with atezolizumab must be permanently discontinued for Grade 3 or 4 pneumonitis.

Immune-mediated hepatitis

Cases of hepatitis, some leading to fatal outcomes have been observed in clinical trials with atezolizumab (see section 4.8). Patients should be monitored for signs and symptoms of hepatitis.

Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and bilirubin should be monitored prior to initiation of treatment, periodically during treatment with atezolizumab and as indicated based on clinical evaluation.

For patients without HCC, treatment with atezolizumab should be withheld if Grade 2 event (ALT or AST > 3 to 5 x ULN or blood bilirubin > 1.5 to 3 x ULN) persists for more than 5 to 7 days, and 1 to 2 mg/kg bw/day of prednisone or equivalent should be started. If the event improves to ≤ Grade 1, corticosteroids should be tapered over ≥ 1 month.

Treatment with atezolizumab may be resumed if the event improves to ≤ Grade 1 within 12 weeks and corticosteroids have been reduced to ≤ 10 mg prednisone or equivalent per day. Treatment with atezolizumab must be permanently discontinued for Grade 3 or Grade 4 events (ALT or AST > 5.0 x ULN or blood bilirubin > 3 x ULN).

For patients with HCC, treatment with atezolizumab should be withheld if ALT or AST increases to > 3 to ≤ 10 x ULN from normal limits at baseline, or > 5 to ≤ 10 x ULN from > 1 ULN to ≤ 3 x ULN at baseline, or > 8 to ≤ 10 x ULN from > 3 ULN to ≤ 5 x ULN at baseline, and persists for more than 5 to 7 days, and 1 to 2 mg/kg bw/day of prednisone or equivalent should be started. If the event improves to ≤ Grade 1, corticosteroids should be tapered over ≥ 1 month.
Treatment with atezolizumab may be resumed if the event improves to ≤ Grade 1 within 12 weeks and corticosteroids have been reduced to ≤ 10 mg prednisone or equivalent per day. Treatment with atezolizumab must be permanently discontinued if ALT or AST increases to > 10 x ULN or total bilirubin increases > 3 x ULN).

**Immune-mediated colitis**

Cases of diarrhoea or colitis have been observed in clinical trials with atezolizumab (see section 4.8). Patients should be monitored for signs and symptoms of colitis.

Treatment with atezolizumab should be withheld for Grade 2 or 3 diarrhoea (increase of ≥ 4 stools/day over baseline) or colitis (symptomatic). For Grade 2 diarrhoea or colitis, if symptoms persist > 5 days or recur, treatment with 1 to 2 mg/kg bw/day prednisone or equivalent should be started. For Grade 3 diarrhoea or colitis, treatment with intravenous corticosteroids (1 to 2 mg/kg bw/day methylprednisolone or equivalent) should be started. Once symptoms improve, treatment with 1 to 2 mg/kg bw/day of prednisone or equivalent should be started. If symptoms improve to ≤ Grade 1, corticosteroids should be tapered over ≥ 1 month. Treatment with atezolizumab may be resumed if the event improves to ≤ Grade 1 within 12 weeks and corticosteroids have been reduced to ≤ 10 mg prednisone or equivalent per day. Treatment with atezolizumab must be permanently discontinued for Grade 4 (life threatening; urgent intervention indicated) diarrhoea or colitis. The potential complication of gastrointestinal perforation associated with colitis should be taken into consideration.

**Immune-mediated endocrinopathies**

Hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis and type 1 diabetes mellitus, including diabetic ketoacidosis have been observed in clinical trials with atezolizumab (see section 4.8).

Patients should be monitored for clinical signs and symptoms of endocrinopathies. Thyroid function should be monitored prior to and periodically during treatment with atezolizumab. Appropriate management of patients with abnormal thyroid function tests at baseline should be considered.

Asymptomatic patients with abnormal thyroid function tests can receive atezolizumab. For symptomatic hypothyroidism, atezolizumab should be withheld and thyroid hormone replacement should be initiated as needed. Isolated hypothyroidism may be managed with replacement therapy and without corticosteroids. For symptomatic hyperthyroidism, atezolizumab should be withheld and an anti-thyroid medicinal product should be initiated as needed. Treatment with atezolizumab may be resumed when symptoms are controlled and thyroid function is improving.

For symptomatic adrenal insufficiency, atezolizumab should be withheld and treatment with intravenous corticosteroids (1 to 2 mg/kg bw/day methylprednisolone or equivalent) should be started. Once symptoms improve, treatment with 1 to 2 mg/kg bw/day of prednisone or equivalent should follow. If symptoms improve to ≤ Grade 1, corticosteroids should be tapered over ≥ 1 month. Treatment may be resumed if the event improves to ≤ Grade 1 within 12 weeks and corticosteroids have been reduced to ≤ 10 mg prednisone or equivalent per day and the patient is stable on replacement therapy (if required).

For Grade 2 or Grade 3 hypophysitis, atezolizumab should be withheld and treatment with intravenous corticosteroids (1 to 2 mg/kg bw/day methylprednisolone or equivalent) should be started, and hormone replacement should be initiated as needed. Once symptoms improve, treatment with 1 to 2 mg/kg bw/day of prednisone or equivalent should follow. If symptoms improve to ≤ Grade 1, corticosteroids should be tapered over ≥ 1 month. Treatment may be resumed if the event improves to ≤ Grade 1 within 12 weeks and corticosteroids have been reduced to ≤ 10 mg prednisone or equivalent per day and the patient is stable on replacement therapy (if required). Treatment with atezolizumab should be permanently discontinued for Grade 4 hypophysitis.
Treatment with insulin should be initiated for type 1 diabetes mellitus. For ≥ Grade 3 hyperglycaemia (fasting glucose > 250 mg/dL or 13.9 mmol/L), atezolizumab should be withheld. Treatment with atezolizumab may be resumed if metabolic control is achieved on insulin replacement therapy.

**Immune-mediated meningoencephalitis**

Meningoencephalitis has been observed in clinical trials with atezolizumab (see section 4.8). Patients should be monitored for clinical signs and symptoms of meningitis or encephalitis.

Treatment with atezolizumab must be permanently discontinued for any grade of meningitis or encephalitis. Treatment with intravenous corticosteroids (1 to 2 mg/kg bw/day methylprednisolone or equivalent) should be started. Once symptoms improve, treatment with 1 to 2 mg/kg bw/day of prednisone or equivalent should follow.

**Immune-mediated neuropathies**

Myasthenic syndrome/myasthenia gravis or Guillain-Barré syndrome, which may be life threatening, and facial paresis were observed in patients receiving atezolizumab. Patients should be monitored for symptoms of motor and sensory neuropathy.

Myelitis has been observed in clinical trials with atezolizumab (see section 4.8). Patients should be closely monitored for signs and symptoms that are suggestive of myelitis.

Treatment with atezolizumab must be permanently discontinued for any grade of myasthenic syndrome/myasthenia gravis or Guillain-Barré syndrome. Initiation of systemic corticosteroids (at a dose of 1 to 2 mg/kg bw/day of prednisone or equivalent) should be considered.

Treatment with atezolizumab should be withheld for Grade 1 or 2 facial paresis, and treatment with systemic corticosteroids (1 to 2 mg/kg bw/day prednisone or equivalent) should be considered. Treatment may be resumed only if the event fully resolves. Treatment with atezolizumab should be permanently discontinued for Grade 3 or Grade 4 facial paresis, or any other neuropathy that does not fully resolve while withholding atezolizumab.

Treatment with atezolizumab must be permanently discontinued for Grade 2, 3 or 4 myelitis.

**Immune-mediated pancreatitis**

Pancreatitis, including increases in serum amylase and lipase levels, has been observed in clinical trials with atezolizumab (see section 4.8). Patients should be closely monitored for signs and symptoms that are suggestive of acute pancreatitis.

Treatment with atezolizumab should be withheld for ≥ Grade 3 serum amylase or lipase levels increased (> 2 x ULN), or Grade 2 or 3 pancreatitis, and treatment with intravenous corticosteroids (1 to 2 mg/kg bw/day methylprednisolone or equivalent) should be started. Once symptoms improve, treatment with 1 to 2 mg/kg bw/day of prednisone or equivalent should follow. Treatment with atezolizumab may be resumed when serum amylase and lipase levels improve to ≤ Grade 1 within 12 weeks, or symptoms of pancreatitis have resolved, and corticosteroids have been reduced to ≤ 10 mg prednisone or equivalent per day. Treatment with atezolizumab should be permanently discontinued for Grade 4, or any grade of recurrent pancreatitis.

**Immune-mediated myocarditis**

Cases of myocarditis, including fatal cases, have been observed with atezolizumab (see section 4.8). Patients should be monitored for signs and symptoms of myocarditis. Myocarditis may also be a clinical manifestation of myositis and should be managed accordingly.
 Patients with cardiac or cardiopulmonary symptoms should be assessed for potential myocarditis, to ensure the initiation of appropriate measures at an early stage. If myocarditis is suspected, treatment with atezolizumab should be withheld, prompt initiation of systemic corticosteroids at a dose of 1 to 2 mg/kg bw/day of prednisone or equivalent should be started, and prompt cardiology consultation with diagnostic workup according to current clinical guidelines should be initiated. Once a diagnosis of myocarditis is established, treatment with atezolizumab must be permanently discontinued for Grade ≥ 2 myocarditis (see section 4.2).

**Immune-mediated nephritis**

Nephritis has been observed in clinical trials with atezolizumab (see section 4.8). Patients should be monitored for changes in renal function.

Treatment with atezolizumab should be withheld for Grade 2 nephritis, and treatment with systemic corticosteroids at a dose of 1 to 2 mg/kg bw/day of prednisone or equivalent should be started. Treatment with atezolizumab may be resumed if the event improves to ≤ Grade 1 within 12 weeks, and corticosteroids have been reduced to ≤ 10 mg prednisone or equivalent per day. Treatment with atezolizumab must be permanently discontinued for Grade 3 or 4 nephritis.

**Immune-mediated myositis**

Cases of myositis, including fatal cases, have been observed with atezolizumab (see section 4.8). Patients should be monitored for signs and symptoms of myositis. Patients with possible myositis should be monitored for signs of myocarditis.

If a patient develops signs and symptoms of myositis, close monitoring should be implemented, and the patient referred to a specialist for assessment and treatment without delay. Treatment with atezolizumab should be withheld for Grade 2 or 3 myositis and corticosteroid therapy (1-2 mg/kg bw/day prednisone or equivalent) should be initiated. If symptoms improve to ≤ Grade 1, taper corticosteroids as clinically indicated. Treatment with atezolizumab may be resumed if the event improves to ≤ Grade 1 within 12 weeks, and corticosteroids have been reduced to ≤ 10 mg oral prednisone or equivalent per day. Treatment with atezolizumab should be permanently discontinued for Grade 4 or grade 3 recurrent myositis, or when unable to reduce the corticosteroid dose to the equivalent of ≤ 10 mg prednisone per day within 12 weeks after onset.

**Immune-mediated severe cutaneous adverse reactions**

Immune-mediated severe cutaneous adverse reactions (SCARs), including cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in patients receiving atezolizumab. Patients should be monitored for suspected severe skin reactions and other causes should be excluded. For suspected SCARs, patients should be referred to a specialist for further diagnosis and management.

Based on the severity of the adverse reaction, atezolizumab should be withheld for Grade 3 skin reactions and treatment with systemic corticosteroids at a dose of 1-2 mg/kg bw/day of prednisone or equivalent should be started. Treatment with atezolizumab may be resumed if the event improves to ≤ Grade 1 within 12 weeks, and corticosteroids have been reduced to ≤ 10 mg prednisone or equivalent per day. Treatment with atezolizumab should be permanently discontinued for Grade 4 skin reactions, and corticosteroids should be administered.

Atezolizumab should be withheld for patients with suspected SJS or TEN. For confirmed SJS or TEN, atezolizumab should be permanently discontinued.

Caution should be used when considering the use of atezolizumab in a patient who has previously experienced a severe or life-threatening skin adverse reaction on prior treatment with other immune-stimulatory anticancer agents.
**Immune-mediated pericardial disorders**

Pericardial disorders, including pericarditis, pericardial effusion and cardiac tamponade, some leading to fatal outcomes, have been observed with atezolizumab (see section 4.8). Patients should be monitored for clinical signs and symptoms of pericardial disorders.

For suspected Grade 1 pericarditis, treatment with atezolizumab should be withheld and prompt cardiology consultation with diagnostic workup according to current clinical guidelines should be initiated. For suspected Grade ≥ 2 pericardial disorders, treatment with atezolizumab should be withheld, prompt treatment with systemic corticosteroids at a dose of 1 to 2 mg/kg bw/day of prednisone or equivalent should be started and prompt cardiology consultation with diagnostic workup according to current clinical guidelines should be initiated. Once a diagnosis of a pericardial disorder event is established, treatment with atezolizumab must be permanently discontinued for Grade ≥ 2 pericardial disorders (see section 4.2).

**Haemophagocytic lymphohistiocytosis**

Haemophagocytic lymphohistiocytosis (HLH), including fatal cases, has been reported in patients receiving atezolizumab (see section 4.8). HLH should be considered when the presentation of cytokine release syndrome is atypical or prolonged. Patients should be monitored for clinical signs and symptoms of HLH. For suspected HLH, atezolizumab must be permanently discontinued and patients should be referred to a specialist for further diagnosis and management.

**Other immune-mediated adverse reactions**

Given the mechanism of action of atezolizumab, other potential immune-mediated adverse reactions may occur, including noninfective cystitis.

Evaluate all suspected immune-mediated adverse reactions to exclude other causes. Patients should be monitored for signs and symptoms of immune-mediated adverse reactions and, based on the severity of the reaction, managed with treatment modifications and corticosteroids as clinically indicated (see section 4.2 and section 4.8).

**Infusion-related reactions**

Infusion-related reactions have been observed with atezolizumab (see section 4.8).

The rate of infusion should be reduced or treatment should be interrupted in patients with Grade 1 or 2 infusion-related reactions. Atezolizumab should be permanently discontinued in patients with Grade 3 or 4 infusion-related reactions. Patients with Grade 1 or 2 infusion-related reactions may continue to receive atezolizumab with close monitoring; premedication with antipyretic and antihistamines may be considered.

**Disease-specific precautions**

*Use of atezolizumab in combination with bevacizumab, paclitaxel and carboplatin in metastatic non-squamous NSCLC*

Physicians should carefully consider the combined risks of the four-drug regimen of atezolizumab bevacizumab, paclitaxel, and carboplatin before initiating treatment (see section 4.8).
Use of atezolizumab in combination with nab-paclitaxel in metastatic TNBC

Neutropenia and peripheral neuropathies occurring during treatment with atezolizumab and nab-paclitaxel may be reversible with interruptions of nab-paclitaxel. Physicians should consult the nab-paclitaxel summary of product characteristics (SmPC) for specific precautions and contraindications of this medicine.

Use of atezolizumab in UC for previously untreated patients who are considered cisplatin ineligible

The baseline and prognostic disease characteristics of the IMvigor210 Cohort 1 study population were overall comparable to patients in the clinic who would be considered cisplatin ineligible but would be eligible for a carboplatin-based combination chemotherapy. There are insufficient data for the subgroup of patients that would be unfit for any chemotherapy; therefore atezolizumab should be used with caution in these patients, after careful consideration of the potential balance of risks and benefits on an individual basis.

Use of atezolizumab in combination with bevacizumab, paclitaxel and carboplatin

Patients with NSCLC that had clear tumour infiltration into the thoracic great vessels or clear cavitation of pulmonary lesions, as seen on imaging, were excluded from the pivotal clinical trial IMpower150 after several cases of fatal pulmonary haemorrhage were observed, which is a known risk factor of treatment with bevacizumab.

In the absence of data, atezolizumab should be used with caution in these populations after careful evaluation of the balance of benefits and risks for the patient.

Use of atezolizumab in combination with bevacizumab, paclitaxel and carboplatin in EGFR+ patients with NSCLC who have progressed on erlotinib+bevacizumab

In study IMpower150, there are no data on the efficacy of atezolizumab in combination with bevacizumab, paclitaxel and carboplatin in EGFR+ patients who have progressed previously on erlotinib+bevacizumab.

Use of atezolizumab in combination with bevacizumab in HCC

Data in HCC patients with Child-Pugh B liver disease treated with atezolizumab in combination with bevacizumab are very limited and there are currently no data available in HCC patients with Child-Pugh C liver disease.

Patients treated with bevacizumab have an increased risk of haemorrhage, and cases of severe gastrointestinal haemorrhage, including fatal events, were reported in patients with HCC treated with atezolizumab in combination with bevacizumab. In patients with HCC, screening for and subsequent treatment of oesophageal varices should be performed as per clinical practice prior to starting treatment with the combination of atezolizumab and bevacizumab. Bevacizumab should be permanently discontinued in patients who experience Grade 3 or 4 bleeding with the combination treatment. Please refer to the bevacizumab Summary of Product Characteristics.

Diabetes mellitus can occur during treatment with atezolizumab in combination with bevacizumab. Physicians should monitor blood glucose levels prior to and periodically during treatment with atezolizumab in combination with bevacizumab as clinically indicated.
Use of atezolizumab as monotherapy for first-line treatment in metastatic NSCLC

Physicians should consider the delayed onset of atezolizumab effect before initiating first-line treatment as monotherapy in patients with NSCLC. A higher number of deaths within 2.5 months after randomisation followed by a long-term survival benefit was observed with atezolizumab compared with chemotherapy. No specific factor(s) associated with early deaths could be identified (see section 5.1).

Patients excluded from clinical trials

Patients with the following conditions were excluded from clinical trials: a history of autoimmune disease, history of pneumonitis, active brain metastasis, HIV, hepatitis B or hepatitis C infection (for non-HCC patients), significant cardiovascular disease and patients with inadequate hematologic and end-organ function. Patients who were administered a live, attenuated vaccine within 28 days prior to enrolment; systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medicinal products within 2 weeks prior to study entry; therapeutic oral or intravenous antibiotics within 2 weeks prior to initiation of study treatment were excluded from clinical trials.

Patient card

The prescriber must discuss the risks of Tecentriq therapy with the patient. The patient will be provided with the patient card and instructed to carry the card at all times.

4.5 Interaction with other medicinal products and other forms of interaction

No formal pharmacokinetic interaction studies have been conducted with atezolizumab. Since atezolizumab is cleared from the circulation through catabolism, no metabolic drug-drug interactions are expected.

The use of systemic corticosteroids or immunosuppressants before starting atezolizumab should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of atezolizumab. However, systemic corticosteroids or other immunosuppressants can be used to treat immune-mediated adverse reactions after starting atezolizumab (see section 4.4).

4.6 Fertility, pregnancy and lactation

Women of childbearing potential

Women of childbearing potential have to use effective contraception during and for 5 months after treatment with atezolizumab.

Pregnancy

There are no data from the use of atezolizumab in pregnant women. No developmental and reproductive studies were conducted with atezolizumab. Animal studies have demonstrated that inhibition of the PD-L1/PD-1 pathway in murine pregnancy models can lead to immune-mediated rejection of the developing foetus resulting in foetal death (see section 5.3). These results indicate a potential risk, based on its mechanism of action, that administration of atezolizumab during pregnancy could cause foetal harm, including increased rates of abortion or stillbirth.

Human immunoglobulins G1 (IgG1) are known to cross the placental barrier and atezolizumab is an IgG1; therefore, atezolizumab has the potential to be transmitted from the mother to the developing foetus.

Atezolizumab should not be used during pregnancy unless the clinical condition of the woman requires treatment with atezolizumab.
Breast-feeding

It is unknown whether atezolizumab is excreted in human milk. Atezolizumab is a monoclonal antibody and is expected to be present in the first milk and at low levels afterwards. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue Tecentriq therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Fertility

No clinical data are available on the possible effects of atezolizumab on fertility. No reproductive and development toxicity studies have been conducted with atezolizumab; however, based on the 26-week repeat dose toxicity study, atezolizumab had an effect on menstrual cycles at an estimated AUC approximately 6 times the AUC in patients receiving the recommended dose and was reversible (see section 5.3). There were no effects on the male reproductive organs.

4.7 Effects on ability to drive and use machines

Tecentriq has minor influence on the ability to drive and use machines. Patients experiencing fatigue should be advised not to drive and use machines until symptoms abate (see section 4.8).

4.8 Undesirable effects

Summary of the safety profile

The safety of atezolizumab as monotherapy is based on pooled data in 4 739 patients across multiple tumour types. The most common adverse reactions (> 10%) were fatigue (29.9%), decreased appetite (20.0%), rash (20.0%), nausea (19.4%), diarrhoea (18.4%), pyrexia (18.3%), cough (18.1%), arthralgia (16.6%), dyspnoea (16.4%), pruritus (13.7%), asthenia (12.9%), back pain (12.5%), vomiting (11.9%), urinary tract infection (11.1%) and headache (10.5%).

The safety of atezolizumab given in combination with other medicinal products, has been evaluated in 4 535 patients across multiple tumour types. The most common adverse reactions (≥ 20%) were anaemia (36.8%), neutropenia (36.6%), nausea (35.5%), fatigue (33.1%), alopecia (28.1%), rash (27.8%), diarrhoea (27.6%), thrombocytopenia (27.1%), constipation (25.8%), decreased appetite (24.7%) and peripheral neuropathy (24.4%).

Use of atezolizumab in the adjuvant NSCLC setting

The safety profile of atezolizumab in the adjuvant setting in the non-small cell lung cancer (NSCLC) patient population (IMpower010) was generally consistent with the overall pooled monotherapy safety profile in the advanced setting. Nevertheless, the incidence of immune-mediated adverse reactions of atezolizumab in IMpower010 was 51.7% compared to 38.4% in the pooled monotherapy population with advanced disease. No new immune-mediated adverse reactions were identified in the adjuvant setting.

Use of atezolizumab in combination with bevacizumab, paclitaxel and carboplatin

In the first-line NSCLC study (IMpower150), an overall higher frequency of adverse events was observed in the four-drug regimen of atezolizumab, bevacizumab, paclitaxel, and carboplatin compared to atezolizumab, paclitaxel and carboplatin, including Grade 3 and 4 events (63.6% compared to 57.5%), Grade 5 events (6.1% compared to 2.5%), adverse events of special interest to atezolizumab (52.4% compared to 48.0%), as well as adverse events leading to withdrawal of any study treatment (33.8% compared to 13.3%). Nausea, diarrhoea, stomatitis, fatigue, pyrexia, mucosal inflammation, decreased appetite, weight decreased, hypertension and proteinuria were reported higher (≥5% difference) in patients receiving atezolizumab in combination with bevacizumab, paclitaxel and carboplatin. Other clinically significant adverse events which were observed more
frequently in the atezolizumab, bevacizumab, paclitaxel, and carboplatin arm were epistaxis, haemoptysis, cerebrovascular accident, including fatal events.

Further details on serious adverse reactions are provided in section 4.4.

Tabulated list of adverse reactions

The adverse reactions (ARs) are listed by MedDRA system organ class (SOC) and categories of frequency in Table 3 for atezolizumab given as monotherapy or as combination therapy. Adverse reactions known to occur with atezolizumab or chemotherapies given alone may occur during treatment with these medicinal products in combination, even if these reactions were not reported in clinical trials with combination therapy. The following categories of frequency have been used: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000), very rare (< 1/10 000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Table 3: Summary of adverse reactions occurring in patients treated with atezolizumab

<table>
<thead>
<tr>
<th>Infections and infestations</th>
<th>Atezolizumab monotherapy</th>
<th>Atezolizumab in combination therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common</td>
<td>urinary tract infection&lt;sup&gt;a&lt;/sup&gt;</td>
<td>lung infection&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Common</td>
<td></td>
<td>sepsis&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>thrombocytopenia&lt;sup&gt;d&lt;/sup&gt;</td>
<td>anaemia, thrombocytopenia&lt;sup&gt;d&lt;/sup&gt;, neutropenia&lt;sup&gt;e&lt;/sup&gt;, leukopenia&lt;sup&gt;f&lt;/sup&gt;</td>
</tr>
<tr>
<td>Common</td>
<td>lymphopenia&lt;sup&gt;e&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Rare</td>
<td>haemophagocytic lymphohistiocytosis</td>
<td>haemophagocytic lymphohistiocytosis</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>infusion-related reaction&lt;sup&gt;h&lt;/sup&gt;</td>
<td>infusion-related reaction&lt;sup&gt;h&lt;/sup&gt;</td>
</tr>
<tr>
<td>Endocrine disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td></td>
<td>hypothryoidism&lt;sup&gt;i&lt;/sup&gt;</td>
</tr>
<tr>
<td>Common</td>
<td>hypothryoidism&lt;sup&gt;i&lt;/sup&gt;, hyperthyroidism&lt;sup&gt;i&lt;/sup&gt;</td>
<td>hyperthyroidism&lt;sup&gt;i&lt;/sup&gt;</td>
</tr>
<tr>
<td>Uncommon</td>
<td>diabetes mellitus&lt;sup&gt;k&lt;/sup&gt;, adrenal insufficiency&lt;sup&gt;i&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Rare</td>
<td>hypophysitis&lt;sup&gt;m&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common</td>
<td>decreased appetite</td>
<td>decreased appetite</td>
</tr>
<tr>
<td>Common</td>
<td>hypokalaemia&lt;sup&gt;ae&lt;/sup&gt;, hyponatraemia&lt;sup&gt;af&lt;/sup&gt;, hyperglycaemia</td>
<td>hypokalaemia&lt;sup&gt;ae&lt;/sup&gt;, hyponatraemia&lt;sup&gt;af&lt;/sup&gt;, hypomagnesaemia&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very Common</td>
<td>headache</td>
<td>peripheral neuropathy&lt;sup&gt;c&lt;/sup&gt;, headache</td>
</tr>
<tr>
<td>Common</td>
<td>syncope, dizziness</td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td>Guillain-Barré syndrome&lt;sup&gt;g&lt;/sup&gt;, meningocencephalitis&lt;sup&gt;g&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Rare</td>
<td>myasthenic syndrome&lt;sup&gt;e&lt;/sup&gt;, facial paresis, myelitis</td>
<td>facial paresis</td>
</tr>
<tr>
<td>Eye disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rare</td>
<td>uveitis</td>
<td></td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rare</td>
<td>myocarditis&lt;sup&gt;s&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>pericardial disorders&lt;sup&gt;ao&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td>pericardial disorders&lt;sup&gt;ao&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Vascular disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very Common</td>
<td></td>
<td>hypertension&lt;sup&gt;ai&lt;/sup&gt;</td>
</tr>
<tr>
<td>Common</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atezolizumab monotherapy</td>
<td>Atezolizumab in combination therapy</td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----------------------------------</td>
<td></td>
</tr>
<tr>
<td>Common hypotension</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory, thoracic, and mediastinal disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common dyspnoea, cough</td>
<td>dyspnoea, cough, nasopharyngitis&lt;sup&gt;hm&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Common pneumonitis&lt;sup&gt;1&lt;/sup&gt;, hypoxia&lt;sup&gt;ag&lt;/sup&gt;, nasopharyngitis&lt;sup&gt;am&lt;/sup&gt;</td>
<td>dysphonia</td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common nausea, vomiting, diarrhoea&lt;sup&gt;u&lt;/sup&gt;</td>
<td>nausea, vomiting diarrhoea&lt;sup&gt;u&lt;/sup&gt;, constipation,</td>
<td></td>
</tr>
<tr>
<td>Common colitis&lt;sup&gt;v&lt;/sup&gt;, abdominal pain, dysphagia, oropharyngeal pain&lt;sup&gt;w&lt;/sup&gt;, dry mouth</td>
<td>stomatitis, dysgeusia</td>
<td></td>
</tr>
<tr>
<td>Uncommon pancreatitis&lt;sup&gt;x&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatobiliary disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common AST increased, ALT increased, hepatitis&lt;sup&gt;y&lt;/sup&gt;</td>
<td>AST increased, ALT increased</td>
<td></td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common rash&lt;sup&gt;z&lt;/sup&gt;, pruritus</td>
<td>rash&lt;sup&gt;z&lt;/sup&gt;, pruritus, alopecia&lt;sup&gt;ab&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Common dry skin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncommon severe cutaneous adverse reactions&lt;sup&gt;ak&lt;/sup&gt;, psoriasis&lt;sup&gt;am&lt;/sup&gt;</td>
<td>severe cutaneous adverse reactions&lt;sup&gt;ak&lt;/sup&gt;, psoriasis&lt;sup&gt;am&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Rare pemphigoid</td>
<td>pemphigoid</td>
<td></td>
</tr>
<tr>
<td><strong>Musculoskeletal and connective tissue disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common arthralgia, back pain</td>
<td>arthralgia, musculoskeletal pain&lt;sup&gt;as&lt;/sup&gt;, back pain</td>
<td></td>
</tr>
<tr>
<td>Common musculoskeletal pain&lt;sup&gt;aa&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncommon myositis&lt;sup&gt;ab&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Renal and urinary disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common blood creatinine increased&lt;sup&gt;c&lt;/sup&gt;</td>
<td>proteinuria&lt;sup&gt;ae&lt;/sup&gt;, blood creatinine increased&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Uncommon nephritis&lt;sup&gt;ad&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not known cystitis noninfective&lt;sup&gt;ae&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very common pyrexia, fatigue, asthenia</td>
<td>pyrexia, fatigue, asthenia, oedema peripheral</td>
<td></td>
</tr>
<tr>
<td>Common influenza like illness, chills</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common blood alkaline phosphatase increased</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Includes reports of urinary tract infection, cystitis, pyelonephritis, escherichia urinary tract infection, urinary tract infection bacterial, kidney infection, pyelonephritis acute, pyelonephritis chronic, pyelitis, renal abscess, streptococcal urinary tract infection, urethritis, urinary tract infection fungal, urinary tract infection pseudomonal.
b Includes reports of pneumonia, bronchitis, lower respiratory tract infection, infectious pleural effusion, tracheobronchitis, atypical pneumonia, lung abscess, infective exacerbation of chronic obstructive airways disease, paracancerous pneumonia, pyopneumothorax, pleural infection, post-procedural pneumonia. 

c Includes reports of blood creatinine increased, hypercreatininaemia. 

Leukopenia 

Includes reports of thrombocytopenia, platelet count decreased. 

Includes reports of neutropenia, neutrophil count decreased, febrile neutropenia, neutropenic sepsis, granulocytopenia. 

Includes reports of white blood cell count decreased, leukopenia. 

Includes reports of lymphopenia, lymphocyte count decreased. 

Includes reports of anti-thyroid antibody positive, autoimmune hypothyroidism, autoimmune thyroiditis, blood thyroid stimulating hormone abnormal, blood thyroid stimulating hormone decreased, blood thyroid stimulating hormone increased, euthyroid sick syndrome, goitre, hypothyroidism, immune-mediated hypothyroidism, myxoedema, myxoedema coma, primary hypothyroidism, thyroid disorder, thyroid hormones decreased, thyroid function test abnormal, thyroiditis, thyroiditis acute, thyroxine decreased, thyroxine free decreased, thyroxine free increased, thyroxine increased, tri-iodothyronine decreased, tri-iodothyronine free abnormal, tri-iodothyronine free decreased, tri-iodothyronine free increased, silent thyroiditis, thyroiditis chronic. 

Includes reports of hyperthyroidism, Basedow’s disease, endocrine ophthalmopathy, exophthalmos. 

Includes reports of diabetes mellitus, type 1 diabetes mellitus, diabetic ketoacidosis, ketoacidosis. 

Includes reports of adrenal insufficiency, blood corticotropin decreased, glucocorticoid deficiency, primary adrenal insufficiency. secondary adrenocortical insufficiency. 

Includes reports of hypophysitis, temperature regulation disorder. 

Includes reports of hypomagnesaemia, blood magnesium decreased. 

Includes reports of neuropathy peripheral, autoimmune neuropathy, peripheral sensory neuropathy, polyneuropathy, herpes zoster, peripheral motor neuropathy, neuralgic amyotrophy, peripheral sensorimotor neuropathy, toxic neuropathy, axonal neuropathy, lumbosacral plexopathy, neuroopathic arthropathy, peripheral nerve infection, neuritis, immune-mediated neuropathy. 

Includes reports of Guillain-Barré syndrome, demyelinating polyneuropathy. 

Includes reports of encephalitis, encephalitis autoimmune, meningitis, photophobia. 

Includes reports of myasthenia gravis. 

Includes reports of myocarditis, autoimmune myocarditis, and immune-mediated myocarditis. 

Includes reports of pneumonitis, lung infiltration, bronchiolitis, immune-mediated pneumonitis, interstitial lung disease, alveolitis, lung opacity, pulmonary toxicity, radiation pneumonitis. 

Includes reports of diarrhea, defaecation urgency, frequent bowel movements, diarrhoea haemorrhagic, gastroduodenal hypermotility. 

Includes reports of colitis, autoimmune colitis, colitis ischaemic, colitis microscopic, colitis ulcerative, diversion colitis, immune-mediated enterocolitis. 

Includes reports of oropharyngeal pain, oropharyngeal discomfort, throat irritation. 

Includes reports of autoimmune pancreatitis, pancreatitis, pancreatitis acute, lipase increased, amylase increased. 

Includes reports of ascites, autoimmune hepatitis, hepatocellular injury, hepatitis, hepatitis acute, hepatitis toxic, hepatotoxicity, liver disorder, drug-induced liver injury, hepatic failure, hepatic steatosis, hepatic lesion, oesophageal varices haemorrhage, varices oesophageal. 

Includes reports of acne, acne pustular, blister, blood blister, dermatis, dermatis aceneform, dermatis allergic, dermatis exfoliative, drug eruption, eczema, eczema infected, erythema, erythema of eyelid, eyelid rash, fixed eruption, folliculitis, furuncle, hand dermatitis, lip blister, oral blood blister, palmar-plantar erythrodysaesthesia syndrome, pemphigoid, rash, rash erythematosus, rash follicular, rash generalised, rash macular, rash maculo-papular, rash papular, rash papulosquamous, rash pruritic, rash pustular, rash vesicular, scrotal dermatitis, seborrhoeic dermatitis, skin exfoliation, skin toxicity, skin ulcer. 

Includes reports of musculoskeletal pain, myalgia, bone pain. 

Includes reports of myositis, rhabdomyolysis, polymyalgia rheumatica, dermatomyositis, muscle abscess, myoglobin urine present.
ac Includes reports of proteinuria, protein urine present, haemoglobinuria, urine abnormality, nephrotic syndrome, albuminuria.
ad Includes reports of nephritis, autoimmune nephritis, Henoch-Schönlein Purpura nephritis, paraneoplastic glomerulonephritis, tubulointerstitial nephritis.
ac Includes reports of hypokalaemia, blood potassium decreased.
af Includes reports of hyponatraemia, blood sodium decreased.
ag Includes reports of hypoxia, oxygen saturation decreased, \( P_O_2 \) decreased.
ah Includes reports of alopecia, madarosis, alopecia areata, alopecia totalis, hypotrichosis.
ai Includes reports of hypertension, blood pressure increased, hypertensive crisis, blood pressure systolic increased, diastolic hypertension, blood pressure inadequately controlled, retinopathy hypertensive, hypertensive nephropathy, essential hypertension, orthostatic hypertension.
aj Includes reports of sepsis, septic shock, urosepsis, neutropenic sepsis, pulmonary sepsis, bacterial sepsis, klebsiella sepsis, abdominal sepsis, candida sepsis, escherichia sepsis, pseudomonal sepsis, staphylococcal sepsis.
ak Includes reports of dermatitis bullous, exfoliative rash, erythema multiforme, dermatitis exfoliative generalised, toxic skin eruption, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, toxic epidermal necrolysis, cutaneous vasculitis.
ao Includes reports of pericarditis, pericardial effusion, cardiac tamponade and pericarditis constrictive.

Description of selected adverse reactions

The data below reflect information for significant adverse reactions for atezolizumab as monotherapy in clinical trials (see section 5.1). Details for the significant adverse reactions for atezolizumab when given in combination are presented if clinically relevant differences were noted in comparison to atezolizumab monotherapy. The management guidelines for these adverse reactions are described in sections 4.2 and 4.4.

**Immune-mediated pneumonitis**

Pneumonitis occurred in 2.9% (138/4 739) of patients who received atezolizumab monotherapy. Of the 138 patients, two experienced fatal events. The median time to onset was 4.0 months (range: 3 days to 29.8 months). The median duration was 1.8 months (range: 1 day to 27.8+ months; + denotes a censored value). Pneumonitis led to discontinuation of atezolizumab in 32 (0.7%) patients. Pneumonitis requiring the use of corticosteroids occurred in 1.7% (80/4 739) of patients receiving atezolizumab monotherapy.

**Immune-mediated hepatitis**

Hepatitis occurred in 1.7% (81/4 739) of patients who received atezolizumab monotherapy. Of the 81 patients, two experienced fatal events. The median time to onset was 1.9 months (range: 6 days to 18.8 months). The median duration was 1.9 months (range: 1 day to 32.4+ months; + denotes a censored value). Hepatitis led to discontinuation of atezolizumab in 16 (0.3%) patients. Hepatitis requiring the use of corticosteroids occurred in 0.6% (27/4 739) of patients receiving atezolizumab monotherapy.

**Immune-mediated colitis**

Colitis occurred in 1.2% (59/4 739) of patients who received atezolizumab monotherapy. The median time to onset was 4.9 months (range: 15 days to 17.2 months). The median duration was 1.4 months (range: 3 days to 50.2+ months; + denotes a censored value). Colitis led to discontinuation of atezolizumab in 22 (0.5%) patients. Colitis requiring the use of corticosteroids occurred in 0.6% (27/4 739) of patients receiving atezolizumab monotherapy.
**Immune-mediated endocrinopathies**

**Thyroid disorders**

Hypothyroidism occurred in 8.4% (400/4739) of patients who received atezolizumab monotherapy. The median time to onset was 4.2 months (range: 1 day to 34.5 months). Hypothyroidism occurred in 17.4% (86/495) of patients who received atezolizumab monotherapy in the adjuvant NSCLC setting. The median time to onset was 4.0 months (range: 22 days to 11.8 months).

Hyperthyroidism occurred in 2.4% (114/4739) of patients who received atezolizumab monotherapy. The median time to onset was 2.76 months (range: 1 day to 24.3 months). Hyperthyroidism occurred in 6.5% (32/495) of patients who received atezolizumab monotherapy in the adjuvant NSCLC setting. The median time to onset was 2.8 months (range: 1 day to 9.9 months).

**Adrenal insufficiency**

Adrenal insufficiency occurred in 0.5% (23/4739) of patients who received atezolizumab monotherapy. The median time to onset was 6.3 months (range: 3 days to 21.4 months). Adrenal insufficiency led to discontinuation of atezolizumab in 5 (0.1%) patients. Adrenal insufficiency requiring the use of corticosteroids occurred in 0.4% (19/4739) of patients receiving atezolizumab monotherapy.

**Hypophysitis**

Hypophysitis occurred in 0.1% (5/4739) of patients who received atezolizumab monotherapy. The median time to onset was 6.9 months (range: 24 days to 13.7 months). Four (< 0.1%) patients required the use of corticosteroids and treatment with atezolizumab was discontinued in 1 (< 0.1%) patient.

Hypophysitis occurred in 0.8% (3/393) of patients who received atezolizumab with bevacizumab, paclitaxel, and carboplatin. The median time to onset was 7.7 months (range: 5.0 to 8.8 months). Two patients required the use of corticosteroids.

Hypophysitis occurred in 0.4% (2/473) of patients who received atezolizumab in combination with nab-paclitaxel and carboplatin. The median time to onset was 5.2 months (range: 5.1 to 5.3 months). Both patients required the use of corticosteroids.

**Diabetes mellitus**

Diabetes mellitus occurred in 0.5% (26/4739) of patients who received atezolizumab monotherapy. The median time to onset was 5.4 months (range: 3 days to 29.0 months). Diabetes mellitus led to the discontinuation of atezolizumab in < 0.1% (3/4739) patients.

Diabetes mellitus occurred in 2.0% (10/493) of HCC patients who received atezolizumab in combination with bevacizumab. The median time to onset was 4.4 months (range: 1.2 months - 8.3 months). No events of diabetes mellitus led to atezolizumab withdrawal.

**Immune-mediated meningoencephalitis**

Meningoencephalitis occurred in 0.5% (22/4739) of patients who received atezolizumab monotherapy. The median time to onset was 16 days (range: 1 day to 12.5 months). The median duration was 24 days (range: 6 days to 14.5+ months; + denotes a censored value).

Meningoencephalitis requiring the use of corticosteroids occurred in 0.3% (12/4739) of patients receiving atezolizumab and eight patients (0.2%) discontinued atezolizumab.
Immune-mediated neuropathies

Guillain-Barré syndrome and demyelinating polyneuropathy

Guillain-Barré syndrome and demyelinating polyneuropathy occurred in 0.1% (6/4,739) of patients who received atezolizumab monotherapy. The median time to onset was 4.1 months (range: 18 days to 8.1 months). The median duration was 8.0 months (range: 18 days to 24.5+ months; + denotes a censored value). Guillain-Barré syndrome led to discontinuation of atezolizumab in 1 patient (< 0.1%). Guillain-Barré syndrome requiring the use of corticosteroids occurred in < 0.1% (3/4,739) of patients receiving atezolizumab monotherapy.

Immune-mediated facial paresis

Facial paresis occurred in < 0.1% (1/4,739) of patients who received atezolizumab monotherapy. The time to onset was 29 days. The duration was 1.1 months. The event did not require the use of corticosteroids and the event did not lead to discontinuation of atezolizumab.

Immune-mediated myelitis

Myelitis occurred in < 0.1% (1/4,739) of patients who received atezolizumab monotherapy. The time to onset was 3 days. The event required the use of corticosteroids but did not lead to discontinuation of atezolizumab.

Myasthenic syndrome

Myasthenia gravis occurred in < 0.1% (1/4,739) of patients who received atezolizumab monotherapy. The time to onset was 1.2 months.

Immune-mediated pancreatitis

Pancreatitis, including amylase increased and lipase increased, occurred in 0.8% (37/4,739) of patients who received atezolizumab monotherapy. The median time to onset was 5.5 months (range: 1 day to 24.8 months). The median duration was 1 month (range: 3 days to 40.4+ months; + denotes a censored value). Pancreatitis led to the discontinuation of atezolizumab in 3 (< 0.1%) patients. Pancreatitis requiring the use of corticosteroids occurred in 0.1% (7/4,739) of patients receiving atezolizumab monotherapy.

Immune-mediated myocarditis

Myocarditis occurred in < 0.1% (4/4,739) of patients who received atezolizumab monotherapy. Of the 4 patients, one experienced a fatal event in the adjuvant NSCLC setting. The median time to onset was 3.4 months (range: 1.5 to 4.9 months). The median duration was 15 days (range: 12 days to 2.8 months). Myocarditis led to the discontinuation of atezolizumab in 3 (< 0.1%) patients. Two (<0.1%) patients required the use of corticosteroids.

Immune-mediated nephritis

Nephritis occurred in 0.2% (11/4,739) of patients who received atezolizumab monotherapy. The median time to onset was 5.1 months (range: 3 days to 17.5 months). Nephritis led to discontinuation of atezolizumab in 5 (0.1%) patients. Five (0.1%) patients required the use of corticosteroids.

Immune-mediated myositis

Myositis occurred in 0.5% (25/4,739) of patients who received atezolizumab monotherapy. The median time to onset was 3.5 months (range: 12 days to 11.5 months). The median duration was 3.2
months (range: 9 days to 51.1+ months; + denotes a censored value). Myositis led to discontinuation of atezolizumab in 6 (0.1%) patients. Seven (0.1%) patients required the use of corticosteroids.

**Immune-mediated severe cutaneous adverse reactions**

Severe cutaneous adverse reactions (SCARs) occurred in 0.6% (30/4,739) of patients who received atezolizumab monotherapy. Of the 30 patients, one experienced a fatal event. The median time to onset was 4.8 months (range: 3 days to 15.5 months). The median duration was 2.4 months (range: 1 day to 37.5+ months; + denotes a censored value). SCARs led to discontinuation of atezolizumab in 3 (< 0.1%) patients. SCARs requiring the use of systemic corticosteroids occurred in 0.2% (9/4,739) of patients receiving atezolizumab monotherapy.

**Immune-mediated pericardial disorders**

Pericardial disorders occurred in 1.0% (48/4,739) of patients who received atezolizumab monotherapy. The median time to onset was 1.4 months (range: 6 days to 17.5 months). The median duration was 1.4 months (range: 1 day to 51.5+ months; + denotes a censored value). Pericardial disorders led to discontinuation of Tecentriq in 3 (< 0.1%) patients. Pericardial disorders requiring the use of corticosteroids occurred in 0.1% (7/4,739) of patients.

**Immunogenicity**

Across multiple phase II and III studies, 13.1% to 54.1% of patients developed treatment-emergent anti-drug antibodies (ADAs). Patients who developed treatment-emergent ADAs tended to have overall poorer health and disease characteristics at baseline. Those imbalances in health and disease characteristics at baseline can confound the interpretation of pharmacokinetic (PK), efficacy and safety analyses. Exploratory analyses adjusting for imbalances in baseline health and disease characteristics were conducted to assess the effect of ADA on efficacy. These analyses did not exclude possible attenuation of efficacy benefit in patients who developed ADA compared to patients who did not develop ADA. The median time to ADA onset ranged from 3 weeks to 5 weeks.

Across pooled datasets for patients treated with atezolizumab monotherapy (N=3,460) and with combination therapies (N= 2,285), the following rates of adverse events (AEs) have been observed for the ADA-positive population compared to the ADA-negative population, respectively: Grade 3-4 AEs 46.2% vs. 39.4%, Serious Adverse Events (SAEs) 39.6% vs. 33.3%, AEs leading to treatment withdrawal 8.5% vs 7.8% (for monotherapy); Grade 3-4 AEs 63.9% vs. 60.9%, SAEs 43.9% vs. 35.6%, AEs leading to treatment withdrawal 22.8% vs 18.4% (for combination therapy). However, available data do not allow firm conclusions to be drawn on possible patterns of adverse reactions.

**Paediatric population**

The safety of atezolizumab in children and adolescents has not been established. No new safety signals were observed in a clinical trial with 69 paediatric patients (< 18 years) and the safety profile was comparable to adults.

**Elderly**

No overall differences in safety were observed between patients ≥ 65 years of age and younger patients receiving atezolizumab monotherapy. In study IMpower150, age ≥ 65 was associated with an increased risk of developing adverse events in patients receiving atezolizumab in combination with bevacizumab, carboplatin and paclitaxel.

In studies IMpower150, IMpower133 and IMpower110, data for patients ≥ 75 years of age are too limited to draw conclusions on this population.
Reporting suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

There is no information on overdose with atezolizumab.

In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic treatment instituted.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies. ATC code: L01FF05

Mechanism of action

Programmed death-ligand 1 (PD-L1) may be expressed on tumour cells and/or tumour-infiltrating immune cells, and can contribute to the inhibition of the antitumour immune response in the tumour microenvironment. Binding of PD-L1 to the PD-1 and B7.1 receptors found on T-cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation and cytokine production.

Atezolizumab is an Fc-engineered, humanised immunoglobulin G1 (IgG1) monoclonal antibody that directly binds to PD-L1 and provides a dual blockade of the PD-1 and B7.1 receptors, releasing PD-L1/PD-1 mediated inhibition of the immune response, including reactivating the antitumour immune response without inducing antibody-dependent cellular cytotoxicity. Atezolizumab spares the PD-L2/PD-1 interaction allowing PD-L2/PD-1 mediated inhibitory signals to persist.

Clinical efficacy and safety

Urothelial carcinoma

IMvigor211 (GO29294): Randomised trial in locally advanced or metastatic UC patients previously treated with chemotherapy

A phase III, open-label, multi-centre, international, randomised study, (IMvigor211), was conducted to evaluate the efficacy and safety of atezolizumab compared with chemotherapy (investigator’s choice of vinflunine, docetaxel, or paclitaxel) in patients with locally advanced or metastatic UC who progressed during or following a platinum-containing regimen. This study excluded patients who had a history of autoimmune disease; active or corticosteroid-dependent brain metastases; administration of a live, attenuated vaccine within 28 days prior to enrolment; and administration of systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medicinal product within 2 weeks prior to enrolment. Tumour assessments were conducted every 9 weeks for the first 54 weeks, and every 12 weeks thereafter. Tumour specimens were evaluated prospectively for PD-L1 expression on tumour-infiltrating immune cells (IC) and the results were used to define the PD-L1 expression subgroups for the analyses described below.

A total of 931 patients were enrolled. Patients were randomised (1:1) to receive either atezolizumab or chemotherapy. Randomisation was stratified by chemotherapy (vinflunine vs. taxane), PD-L1 expression status on IC (< 5% vs. ≥ 5%), number of prognostic risk factors (0 vs. 1-3), and liver...
metastases (yes vs. no). Prognostic risk factors included time from prior chemotherapy of < 3 months, ECOG performance status > 0 and haemoglobin < 10 g/dL.

Atezolizumab was administered as a fixed dose of 1 200 mg by intravenous infusion every 3 weeks. No dose reduction of atezolizumab was allowed. Patients were treated until loss of clinical benefit as assessed by the investigator or unacceptable toxicity. Vinflunine was administered 320 mg/m² by intravenous infusion on day 1 of each 3-week cycle until disease progression or unacceptable toxicity. Paclitaxel was administered 175 mg/m² by intravenous infusion over 3 hours on day 1 of each 3-week cycle until disease progression or unacceptable toxicity. Docetaxel was administered 75 mg/m² by intravenous infusion on day 1 of each 3-week cycle until disease progression or unacceptable toxicity. For all treated patients, the median duration of treatment was 2.8 months for the atezolizumab arm, 2.1 months for the vinflunine and paclitaxel arms and 1.6 months for the docetaxel arm.

The demographic and baseline disease characteristics of the primary analysis population were well balanced between the treatment arms. The median age was 67 years (range: 31 to 88), and 77.1% of patients were male. The majority of patients were white (72.1%), 53.9% of patients within the chemotherapy arm received vinflunine, 71.4% of patients had at least one poor prognostic risk factor and 28.8% had liver metastases at baseline. Baseline ECOG performance status was 0 (45.6%) or 1 (54.4%). Bladder was the primary tumour site for 71.1% of patients and 25.4% of patients had upper tract UC. There were 24.2% of patients who received only prior platinum-containing adjuvant or neoadjuvant therapy and progressed within 12 months.

The primary efficacy endpoint for IMvigor211 is overall survival (OS). Secondary efficacy endpoints evaluated per investigator-assessed Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 are objective response rate (ORR), progression-free survival (PFS), and duration of response (DOR). Comparisons with respect to OS between the treatment arm and control arm within the IC2/3, IC1/2/3, and ITT (Intention-to-treat, i.e. all comers) populations were tested using a hierarchical fixed-sequence procedure based on a stratified log-rank test at two-sided level of 5% as follows: step 1) IC2/3 population; step 2) IC1/2/3 population; step 3) all comers population. OS results for each of steps 2 and 3 could be formally tested for statistical significance only if the result in the preceding step was statistically significant.

The median survival follow-up is 17 months. The primary analysis of study IMvigor211 did not meet its primary endpoint of OS. Atezolizumab did not demonstrate a statistically significant survival benefit compared to chemotherapy in patients with previously treated, locally advanced or metastatic UC. Per the pre-specified hierarchical testing order, the IC2/3 population was tested first, with an OS HR of 0.87 (95% CI: 0.63, 1.21; median OS of 11.1 vs. 10.6 months for atezolizumab and chemotherapy respectively). The stratified log-rank p-value was 0.41 and therefore the results are considered not statistically significant in this population. As a consequence, no formal tests of statistical significance could be performed for OS in the IC1/2/3 or all comers populations, and results of those analyses would be considered exploratory. The key results in the all comers population are summarised in Table 4. The Kaplan-Meier curve for OS in the all comers population is presented in Figure 1.

An exploratory updated survival analysis was performed with a median duration of survival follow up of 34 months in the ITT population. The median OS was 8.6 months (95% CI: 7.8, 9.6) in the atezolizumab arm and 8.0 months (95% CI: 7.2, 8.6) in the chemotherapy arm with a hazard ratio of 0.82 (95% CI: 0.71, 0.94). Consistent with the trend observed at primary analysis for 12-month OS rates, numerically higher 24-month and 30-month OS rates were observed for patients in the atezolizumab arm compared with the chemotherapy arm in the ITT population. The percentage of patients alive at 24 months (KM estimate) was 12.7% in the chemotherapy arm and 22.5% in the atezolizumab arm; and at 30 months (KM estimate) was 9.8% in the chemotherapy arm and 18.1% in the atezolizumab arm.
Table 4: Summary of efficacy in all comers (IMvigor211)

<table>
<thead>
<tr>
<th>Efficacy endpoint</th>
<th>Atezolizumab (n = 467)</th>
<th>Chemotherapy (n = 464)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary efficacy endpoint</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OS*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of deaths (%)</td>
<td>324 (69.4%)</td>
<td>350 (75.4%)</td>
</tr>
<tr>
<td>Median time to events (months)</td>
<td>8.6</td>
<td>8.0</td>
</tr>
<tr>
<td>95% CI</td>
<td>7.8, 9.6</td>
<td>7.2, 8.6</td>
</tr>
<tr>
<td>Stratified† hazard ratio (95% CI)</td>
<td>0.85 (0.73, 0.99)</td>
<td></td>
</tr>
<tr>
<td>12-month OS (%)**</td>
<td>39.2%</td>
<td>32.4%</td>
</tr>
<tr>
<td><strong>Secondary and exploratory endpoints</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigator-assessed PFS (RECIST v1.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of events (%)</td>
<td>407 (87.2%)</td>
<td>410 (88.4%)</td>
</tr>
<tr>
<td>Median duration of PFS (months)</td>
<td>2.1</td>
<td>4.0</td>
</tr>
<tr>
<td>95% CI</td>
<td>2.1, 2.2</td>
<td>3.4, 4.2</td>
</tr>
<tr>
<td>Stratified hazard ratio (95% CI)</td>
<td>1.10 (0.95, 1.26)</td>
<td></td>
</tr>
<tr>
<td>Investigator-assessed ORR (RECIST v1.1)</td>
<td>n = 462</td>
<td>n = 461</td>
</tr>
<tr>
<td>No. of confirmed responders (%)</td>
<td>62 (13.4%)</td>
<td>62 (13.4%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>10.45, 16.87</td>
<td>10.47, 16.91</td>
</tr>
<tr>
<td>No. of complete response (%)</td>
<td>16 (3.5%)</td>
<td>16 (3.5%)</td>
</tr>
<tr>
<td>No. of partial response (%)</td>
<td>46 (10.0%)</td>
<td>46 (10.0%)</td>
</tr>
<tr>
<td>No. of stable disease (%)</td>
<td>92 (19.9%)</td>
<td>162 (35.1%)</td>
</tr>
<tr>
<td>Investigator-assessed DOR (RECIST v1.1)</td>
<td>n = 62</td>
<td>n = 62</td>
</tr>
<tr>
<td>Median in months ***</td>
<td>21.7</td>
<td>7.4</td>
</tr>
<tr>
<td>95% CI</td>
<td>13.0, 21.7</td>
<td>6.1, 10.3</td>
</tr>
</tbody>
</table>

CI = confidence interval; DOR = duration of response; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; RECIST = Response Evaluation Criteria in Solid Tumours v1.1.

* An analysis of OS in the all comer population was performed based on the stratified log-rank test and the result is provided for descriptive purposes only (p = 0.0378); according to the pre-specified analysis hierarchy, the p-value for the OS analysis in the all comer population cannot be considered statistically significant.

† Stratified by chemotherapy (vinflunine vs. taxane), status on IC (< 5% vs. ≥ 5%), number of prognostic risk factors (0 vs. 1-3), and liver metastases (yes vs. no).

** Based on Kaplan-Meier estimate

*** Responses were ongoing in 63% of responders in the atezolizumab arm and in 21% of responders in the chemotherapy arm.
IMvigor210 (GO29293): Single-arm trial in previously untreated urothelial carcinoma patients who are ineligible for cisplatin therapy and in urothelial carcinoma patients previously treated with chemotherapy

A phase II, multi-centre, international, two-cohort, single-arm clinical trial, IMvigor210, was conducted in patients with locally advanced or metastatic UC (also known as urothelial bladder cancer).

The study enrolled a total of 438 patients and had two patient cohorts. Cohort 1 included previously untreated patients with locally advanced or metastatic UC who were ineligible or unfit for cisplatin-based chemotherapy or had disease progression at least 12 months after treatment with a platinum-containing neoadjuvant or adjuvant chemotherapy regimen. Cohort 2 included patients who received at least one platinum-based chemotherapy regimen for locally advanced or metastatic UC or had disease progression within 12 months of treatment with a platinum-containing neoadjuvant or adjuvant chemotherapy regimen.

In Cohort 1, 119 patients were treated with atezolizumab 1 200 mg by intravenous infusion every 3 weeks until disease progression. The median age was 73 years. Most patients were male (81%), and the majority of patients were White (91%).

Cohort 1 included 45 patients (38%) with ECOG performance status of 0, 50 patients (42%) with ECOG performance status of 1 and 24 patients (20%) with ECOG performance status of 2, 35 patients (29%) with no Bajorin risk factors (ECOG performance status ≥ 2 and visceral metastasis), 66 patients (56%) with one Bajorin risk factor and 18 patients (15 %) with two Bajorin risk factors, 84 patients (71%) with impaired renal function (glomerular filtration rate [GFR] < 60 mL/min), and 25 patients (21%) with liver metastasis.

The primary efficacy endpoint for Cohort 1 was confirmed objective response rate (ORR) as assessed by an independent review facility (IRF) using RECIST v1.1.

The primary analysis was performed when all patients had at least 24 weeks of follow-up. Median duration of treatment was 15.0 weeks and median duration of survival follow-up was 8.5 months in all comers. Clinically relevant IRF-assessed ORRs per RECIST v1.1 were shown; however, when compared to a pre-specified historical control response rate of 10%, statistical significance was not reached for the primary endpoint. The confirmed ORRs per IRF-RECIST v1.1 were 21.9% (95% CI:
9.3, 40.0) in patients with PD-L1 expression ≥ 5%, 18.8% (95% CI: 10.9, 29.0) in patients with PD-L1 expression ≥ 1%, and 19.3% (95% CI: 12.7, 27.6) in all comers. The median duration of response (DOR) was not reached in any PD-L1 expression subgroup or in all comers. OS was not mature with an event patient ratio of approximately 40%. Median OS for all patient subgroups (PD-L1 expression ≥ 5% and ≥ 1%) and in all comers was 10.6 months.

An updated analysis was performed with a median duration of survival follow-up of 17.2 months for Cohort 1 and is summarised in Table 5. The median DOR was not reached in any PD-L1 expression subgroup or in all comers.

**Table 5: Summary of updated efficacy (IMvigor210 Cohort 1)**

<table>
<thead>
<tr>
<th>Efficacy endpoint</th>
<th>PD-L1 expression of ≥ 5% in IC</th>
<th>PD-L1 expression of ≥ 1% in IC</th>
<th>All Comers</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORR (IRF-assessed; RECIST v1.1)</td>
<td>n = 32</td>
<td>n = 80</td>
<td>n = 119</td>
</tr>
<tr>
<td>No. of Responders (%)</td>
<td>9 (28.1%)</td>
<td>19 (23.8%)</td>
<td>27 (22.7%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>13.8, 46.8</td>
<td>15.0, 34.6</td>
<td>15.5, 31.3</td>
</tr>
<tr>
<td>No. of complete response (%)</td>
<td>4 (12.5%)</td>
<td>8 (10.0%)</td>
<td>11 (9.2%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>(3.5, 29.0)</td>
<td>(4.4, 18.8)</td>
<td>(4.7, 15.9)</td>
</tr>
<tr>
<td>No. of partial response (%)</td>
<td>5 (15.6%)</td>
<td>11 (13.8%)</td>
<td>16 (13.4%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>(5.3, 32.8)</td>
<td>(7.1, 23.3)</td>
<td>(7.9, 20.9)</td>
</tr>
<tr>
<td>DOR (IRF-assessed; RECIST v1.1)</td>
<td>n = 9</td>
<td>n = 19</td>
<td>n = 27</td>
</tr>
<tr>
<td>Patients with event (%)</td>
<td>3 (33.3%)</td>
<td>5 (26.3%)</td>
<td>8 (29.6%)</td>
</tr>
<tr>
<td>Median (months) (95% CI)</td>
<td>NE (11.1, NE)</td>
<td>NE (NE)</td>
<td>NE (14.1, NE)</td>
</tr>
<tr>
<td>PFS (IRF-assessed; RECIST v1.1)</td>
<td>n = 32</td>
<td>n = 80</td>
<td>n = 119</td>
</tr>
<tr>
<td>Patients with event (%)</td>
<td>24 (75.0%)</td>
<td>59 (73.8%)</td>
<td>88 (73.9%)</td>
</tr>
<tr>
<td>Median (months) (95% CI)</td>
<td>4.1 (2.3, 11.8)</td>
<td>2.9 (2.1, 5.4)</td>
<td>2.7 (2.1, 4.2)</td>
</tr>
<tr>
<td>OS</td>
<td>n = 32</td>
<td>n = 80</td>
<td>n = 119</td>
</tr>
<tr>
<td>Patients with event (%)</td>
<td>18 (56.3%)</td>
<td>42 (52.5%)</td>
<td>59 (49.6%)</td>
</tr>
<tr>
<td>Median (months) (95% CI)</td>
<td>12.3 (6.0, NE)</td>
<td>14.1 (9.2, NE)</td>
<td>15.9 (10.4, NE)</td>
</tr>
<tr>
<td>1-year OS rate (%)</td>
<td>52.4%</td>
<td>54.8%</td>
<td>57.2%</td>
</tr>
</tbody>
</table>

CI = confidence interval; DOR = duration of response; IC = tumour-infiltrating immune cells; IRF = independent review facility; NE = not estimable; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; RECIST = Response Evaluation Criteria in Solid Tumours v1.1.

In Cohort 2, the co-primary efficacy endpoints were confirmed ORR as assessed by an IRF using RECIST v1.1 and investigator-assessed ORR according to Modified RECIST (mRECIST) criteria. There were 310 patients treated with atezolizumab 1 200 mg by intravenous infusion every 3 weeks until loss of clinical benefit. The primary analysis of Cohort 2 was performed when all patients had at least 24 weeks of follow-up. The study met its co-primary endpoints in Cohort 2, demonstrating statistically significant ORRs per IRF-assessed RECIST v1.1 and investigator-assessed mRECIST compared to a pre-specified historical control response rate of 10%.

An analysis was also performed with a median duration of survival follow-up of 21.1 months for Cohort 2. The confirmed ORRs per IRF-RECIST v1.1 were 28.0% (95% CI: 19.5, 37.9) in patients with PD-L1 expression ≥ 5%, 19.3% (95% CI: 14.2, 25.4) in patients with PD-L1 expression ≥ 1%, and 15.8% (95% CI: 11.9, 20.4) in all comers. The confirmed ORR per investigator-assessed mRECIST was 29.0% (95% CI: 20.4, 38.9) in patients with PD-L1 expression ≥ 5%, 23.7% (95% CI:
18.1, 30.1) in patients with PD-L1 expression $\geq$ 1%, and 19.7% (95% CI: 15.4, 24.6) in all comers. The rate of complete response per IRF-RECIST v1.1 in the all comer population was 6.1% (95% CI: 3.7, 9.4). For Cohort 2, median DOR was not reached in any PD-L1 expression subgroup or in all comers, however was reached in patients with PD-L1 expression < 1% (13.3 months; 95% CI 4.2, NE). The OS rate at 12 months was 37% in all comers.

**IMvigor130 (WO30070): Phase III study of atezolizumab monotherapy and in combination with platinum-based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma**

A phase III, multi-centre, randomised, placebo-controlled, partially blinded (Arms A and C only) study, IMvigor130, was conducted to evaluate the efficacy and safety of atezolizumab + platinum-based combination chemotherapy (i.e., either cisplatin or carboplatin with gemcitabine), Arm A, or atezolizumab monotherapy (Arm B, open-label arm) versus placebo + platinum-based combination chemotherapy (Arm C) in patients with locally advanced or metastatic UC who had not received prior systemic therapy in the metastatic setting. The co-primary efficacy outcomes were investigator-assessed progression-free survival (PFS) in Arm A versus Arm C and overall survival (OS) in Arm A versus C and then Arm B versus C, analyzed in a hierarchical fashion. Overall survival was not statistically significant for the comparison of Arm A versus Arm C, and thus no further formal testing could be conducted per the pre-defined hierarchical testing order.

Based on an independent Data Monitoring Committee (iDMC) recommendation following an early review of survival data, accrual of patients on the atezolizumab monotherapy treatment arm whose tumours had a low PD-L1 expression (less than 5% of immune cells staining positive for PD-L1 by immunohistochemistry using VENTANA PD-L1 [SP142] assay) was stopped after observing decreased overall survival for this subgroup at an unplanned early analysis, however, this occurred after the vast majority of patients had already been enrolled.

Out of 719 patients enrolled in the atezolizumab monotherapy (n=360) and chemotherapy alone (n=359) arms, 50 and 43 patients, respectively, were cisplatin-ineligible by Galsky criteria and had tumours with high PD-L1 expression ($\geq$ 5% of immune cells staining positive for PD-L1 by immunohistochemistry using VENTANA PD-L1 [SP142] assay). In an exploratory analysis in this subgroup of patients, the unstratified HR for OS was 0.56 (95% CI: 0.34, 0.91). The median OS was 18.6 months (95% CI: 14.0, 49.4) in the atezolizumab monotherapy arm vs. 10.0 months (95% CI: 7.4, 18.1) in the chemotherapy alone arm (see Figure 2).

**Figure 2 Kaplan-Meier Plot of Overall Survival in Cisplatin-ineligible patients whose tumours are PD-L1 high (Arm B vs. Arm C)**
**Non-small cell lung cancer**

**Adjuvant treatment of early-stage NSCLC**

**IMpower010 (GO29527): Randomised phase III trial in patients with resected NSCLC after cisplatin-based chemotherapy**

A phase III, open label, multi-centre, randomised study, GO29527 (IMpower010), was conducted to evaluate the efficacy and safety of atezolizumab for the adjuvant treatment of patients with stage IB (tumours ≥ 4 cm) – IIIA NSCLC (per the Union for International Cancer Control/American Joint Committee on Cancer staging system, 7th edition).

The following selection criteria define patients with high risk of recurrence who are included in the therapeutic indication and are reflective of the patient population with stage II – IIIA according to the 7th edition staging system:

- Tumour size ≥ 5 cm; or tumours of any size that are either accompanied by N1 or N2 status; or tumours that are invasive of thoracic structures (directly invade the parietal pleura, chest wall, diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, oesophagus, vertebral body, carina); or tumours that involve the main bronchus < 2 cm distal to the carina but without involvement of the carina; or tumours that are associated with atelectasis or obstructive pneumonitis of the entire lung; or tumours with separate nodule(s) in the same lobe or different ipsilateral lobe as the primary.

The study did not include patients who had N2 status with tumours invading the mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, oesophagus, vertebral body, carina, or with separate tumour nodule(s) in a different ipsilateral lobe.

A total of 1 280 enrolled patients had complete tumour resection and were eligible to receive up to 4 cycles of cisplatin-based chemotherapy. The cisplatin-based chemotherapy regimens are described in Table 6.

**Table 6: Adjuvant chemotherapy regimens (IMpower010)**

<table>
<thead>
<tr>
<th>Adjuvant cisplatin-based chemotherapy: Cisplatin 75 mg/m² intravenous on Day 1 of each 21 day cycle with one of the following treatment regimens</th>
<th>Vinorelbine 30 mg/m² intravenous, Days 1 and 8</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Docetaxel 75 mg/m² intravenous, Day 1</td>
</tr>
<tr>
<td></td>
<td>Gemcitabine 1 250 mg/m² intravenous, Days 1 and 8</td>
</tr>
<tr>
<td></td>
<td>Pemetrexed 500 mg/m² intravenous, Day 1(non-squamous)</td>
</tr>
</tbody>
</table>

After completion of cisplatin-based chemotherapy (up to four cycles), a total of 1 005 patients were randomised in a 1:1 ratio to receive atezolizumab (Arm A) or best supportive care (BSC) (Arm B). Atezolizumab was administered as a fixed dose of 1 200 mg by IV infusion every 3 weeks for 16 cycles unless there was disease recurrence or unacceptable toxicity. Randomisation was stratified by sex, stage of disease, histology, and PD-L1 expression.

Patients were excluded if they had a history of autoimmune disease; administration of a live, attenuated vaccine within 28 days prior to randomisation; administration of systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medications within 2 weeks prior to randomisation. Tumour assessments were conducted at baseline of the randomisation phase and every 4 months for the first year following Cycle 1, Day 1 and then every 6 months until year five, then annually thereafter.

The demographics and baseline disease characteristics in the ITT population were well balanced between the treatment arms. The median age was 62 years (range: 26 to 84), and 67% of patients were
male. The majority of patients were White (73%), and 24% were Asian. Most patients were current or previous smokers (78%) and baseline ECOG performance status in patients was 0 (55%) or 1 (44%). Overall, 12% of patients had stage IB, 47% had stage II and 41% had stage IIIA disease. The percentage of patients who had tumours with PD-L1 expression ≥ 1% and ≥ 50% on TC as measured by the VENTANA PD-L1 (SP263) Assay was 55% and 26%, respectively.

The primary efficacy outcome measure was disease-free survival (DFS) as assessed by the investigator. DFS was defined as the time from the date of randomisation to the date of occurrence of any of the following: first documented recurrence of disease, new primary NSCLC, or death due to any cause, whichever occurred first. The primary efficacy objective was to evaluate DFS in the PD-L1 ≥ 1% TC stage II – IIIA patient population. Key secondary efficacy objectives were to evaluate DFS in the PD-L1 ≥ 50% TC stage II – IIIA patient population and overall survival (OS) in the ITT population.

At the time of the interim DFS analysis, the study met its primary endpoint. The median follow-up time was approximately 32 months. In the analysis of patients with PD-L1 ≥ 50% TC stage II – IIIA without EGFR mutations or ALK rearrangements (n = 209), a clinically meaningful improvement in DFS in the atezolizumab arm was observed compared to the BSC arm (Table 7). The OS data were immature at the time of the DFS interim analysis with approximately 16.3 % of deaths overall reported in the PD-L1 ≥ 50% TC stage II – IIIA patient population, without EGFR mutations and ALK rearrangements. An exploratory analysis of OS suggested a trend in favor of atezolizumab over BSC, with a stratified HR of 0.39 (95% CI: 0.18, 0.82) in this patient population.

The key efficacy results for the PD-L1 ≥ 50% TC stage II – IIIA patient population, without EGFR mutations and ALK rearrangements, are summarised in Table 7. The Kaplan-Meier curve for DFS is presented in Figure 3.

Table 7: Summary of efficacy in the PD-L1 expression ≥ 50% TC stage II – IIIA patient population without EGFR mutations or ALK rearrangements (IMpower010)

<table>
<thead>
<tr>
<th>Efficacy endpoint</th>
<th>Arm A (Atezolizumab)</th>
<th>Arm B (Best supportive care)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigator-assessed DFS</td>
<td>n = 106</td>
<td>n = 103</td>
</tr>
<tr>
<td>No. of events (%)</td>
<td>24 (22.6%)</td>
<td>45 (43.7%)</td>
</tr>
<tr>
<td>Median duration of DFS (months)</td>
<td>NE</td>
<td>37.3</td>
</tr>
<tr>
<td>95% CI</td>
<td>NE, NE</td>
<td>30.1, NE</td>
</tr>
<tr>
<td>Stratified hazard ratio (95% CI)</td>
<td>0.49 (0.29, 0.81)</td>
<td></td>
</tr>
<tr>
<td>3-year DFS rate (%)</td>
<td>75.1</td>
<td>50.4</td>
</tr>
</tbody>
</table>

DFS = Disease-free survival; CI = confidence interval; NE = not estimable
The observed DFS improvement in the atezolizumab arm compared with the BSC arm was consistently shown across the majority of pre-specified subgroups in the PD-L1 ≥ 50% TC stage II – IIIA patient population without EGFR mutations or ALK rearrangements, including both non-squamous NSCLC patients (unstratified HR of 0.35, 95% CI: 0.18, 0.69; median DFS NE vs. 35.7 months) and squamous NSCLC patients (unstratified HR of 0.60, 95% CI: 0.29, 1.26; median DFS 36.7 vs. NE months).

First-line treatment of metastatic NSCLC

IMpower150 (GO29436): Randomised phase III trial in chemotherapy-naïve patients with metastatic non-squamous NSCLC, in combination with paclitaxel and carboplatin with or without bevacizumab

A phase III, open-label, multi-centre, international, randomised study, IMpower150, was conducted to evaluate the efficacy and safety of atezolizumab in combination with paclitaxel and carboplatin, with or without bevacizumab, in chemotherapy-naïve patients with metastatic non-squamous NSCLC.

Patients were excluded if they had history of autoimmune disease, administration of a live, attenuated vaccine within 28 days prior to randomisation, administration of systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medicinal product within 2 weeks prior to randomisation, active or untreated CNS metastases, clear tumour infiltration into the thoracic great vessels or clear cavitation of pulmonary lesions, as seen on imaging. Tumour assessments were conducted every 6 weeks for the first 48 weeks following Cycle 1, Day 1 and then every 9 weeks thereafter. Tumour specimens were evaluated for PD-L1 expression on tumour cells (TC) and tumour-infiltrating immune cells (IC) and the results were used to define the PD-L1 expression subgroups for the analyses described below.

A total of 1 202 patients were enrolled and were randomised (1:1:1) to receive one of the treatment regimens described in Table 8. Randomisation was stratified by sex, presence of liver metastases and PD-L1 tumour expression on TC and IC.
Table 8: Intravenous treatment regimens (IMpower150)

<table>
<thead>
<tr>
<th>Treatment regimen</th>
<th>Induction (Four or Six 21-day cycles)</th>
<th>Maintenance (21-day cycles)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Atezolizumab(^a) (1 200 mg) + paclitaxel (200 mg/m(^2)) + carboplatin(^c) (AUC 6)</td>
<td>Atezolizumab(^a) (1 200 mg)</td>
</tr>
<tr>
<td>B</td>
<td>Atezolizumab(^a) (1 200 mg) + bevacizumab(^d) (15 mg/kg bw) + paclitaxel (200 mg/m(^2)) + carboplatin(^c) (AUC 6)</td>
<td>Atezolizumab(^a) (1 200 mg) + bevacizumab(^d) (15 mg/kg bw)</td>
</tr>
<tr>
<td>C</td>
<td>Bevacizumab(^d) (15 mg/kg bw) + paclitaxel (200 mg/m(^2)) + carboplatin(^c) (AUC 6)</td>
<td>Bevacizumab(^d) (15 mg/kg bw)</td>
</tr>
</tbody>
</table>

\(^a\) Atezolizumab is administered until loss of clinical benefit as assessed by the investigator.
\(^b\) The paclitaxel starting dose for patients of Asian race/ethnicity was 175 mg/m\(^2\) due to higher overall level of haematologic toxicities in patients from Asian countries compared with those from non-Asian countries.
\(^c\) Paclitaxel and carboplatin are administered until completion of 4 or 6 cycles, or progressive disease, or unacceptable toxicity whichever occurs first.
\(^d\) Bevacizumab is administered until progressive disease or unacceptable toxicity.

The demographics and baseline disease characteristics of the study population were well balanced between the treatment arms. The median age was 63 years (range: 31 to 90), and 60% of patients were male. The majority of patients were white (82%). Approximately 10% of patients had known EGFR mutation, 14% had known ALK rearrangements, 14% had liver metastasis at baseline, and most patients were current or previous smokers (80%). Baseline ECOG performance status was 0 (43%) or 1 (57%). 51% of patients’ tumours had PD-L1 expression of ≥ 1% TC or ≥ 1% IC and 49% of patients’ tumours had PD-L1 expression of < 1% TC and < 1% IC.

At the time of the final analysis for PFS, patients had a median follow up time of 15.3 months. The ITT population, including patients with EGFR mutations or ALK rearrangements who should have been previously treated with tyrosine kinase inhibitors, demonstrated clinically meaningful PFS improvement in Arm B as compared to Arm C (HR of 0.61, 95% CI: 0.52, 0.72; median PFS 8.3 vs. 6.8 months).

At the time of the interim OS analysis, patients had a median follow-up of 19.7 months. The key results from this analysis as well as from the updated PFS analysis in the ITT population are summarised in Tables 9 and 10. The Kaplan-Meier curve for OS in the ITT population is presented in Figure 4. Figure 5 summarises the results of OS in the ITT and PD-L1 subgroups. Updated PFS results are also presented in Figures 6 and 7.
Table 9: Summary of updated efficacy in the ITT population (IMpower150)

<table>
<thead>
<tr>
<th>Efficacy endpoint</th>
<th>Arm A (Atezolizumab + Paclitaxel + Carboplatin)</th>
<th>Arm B (Atezolizumab + Bevacizumab + Paclitaxel + Carboplatin)</th>
<th>Arm C (Bevacizumab + Paclitaxel + Carboplatin)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Secondary Endpoints</strong>&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Investigator-assessed PFS (RECIST v1.1)</strong>&lt;sup&gt;*&lt;/sup&gt;</td>
<td>n = 402</td>
<td>n = 400</td>
<td>n = 400</td>
</tr>
<tr>
<td>No. of events (%)</td>
<td>330 (82.1%)</td>
<td>291 (72.8%)</td>
<td>355 (88.8%)</td>
</tr>
<tr>
<td>Median duration of PFS (months)</td>
<td>6.7</td>
<td>8.4</td>
<td>6.8</td>
</tr>
<tr>
<td>95% CI</td>
<td>(5.7, 6.9)</td>
<td>(8.0, 9.9)</td>
<td>(6.0, 7.0)</td>
</tr>
<tr>
<td>Stratified hazard ratio&lt;sup&gt;v&lt;/sup&gt; (95% CI)</td>
<td>0.91 (0.78, 1.06)</td>
<td>0.59 (0.50, 0.69)</td>
<td>---</td>
</tr>
<tr>
<td>p-value&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td>0.2194</td>
<td>&lt; 0.0001</td>
<td>---</td>
</tr>
<tr>
<td>12-month PFS (%)</td>
<td>24</td>
<td>38</td>
<td>20</td>
</tr>
<tr>
<td><strong>OS interim analysis</strong>&lt;sup&gt;*&lt;/sup&gt;</td>
<td>n = 402</td>
<td>n = 400</td>
<td>n = 400</td>
</tr>
<tr>
<td>No. of deaths (%)</td>
<td>206 (51.2%)</td>
<td>192 (48.0%)</td>
<td>230 (57.5%)</td>
</tr>
<tr>
<td>Median time to events (months)</td>
<td>19.5</td>
<td>19.8</td>
<td>14.9</td>
</tr>
<tr>
<td>95% CI</td>
<td>(16.3, 21.3)</td>
<td>(17.4, 24.2)</td>
<td>(13.4, 17.1)</td>
</tr>
<tr>
<td>Stratified hazard ratio&lt;sup&gt;v&lt;/sup&gt; (95% CI)</td>
<td>0.85 (0.71, 1.03)</td>
<td>0.76 (0.63, 0.93)</td>
<td>---</td>
</tr>
<tr>
<td>p-value&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td>0.0983</td>
<td>0.006</td>
<td>---</td>
</tr>
<tr>
<td>6-month OS (%)</td>
<td>84</td>
<td>85</td>
<td>81</td>
</tr>
<tr>
<td>12-month OS (%)</td>
<td>66</td>
<td>68</td>
<td>61</td>
</tr>
<tr>
<td><strong>Investigator-assessed Overall Best Response</strong>&lt;sup&gt;3&lt;/sup&gt; (RECIST 1.1)</td>
<td>n = 401</td>
<td>n = 397</td>
<td>n = 393</td>
</tr>
<tr>
<td>No. of responders (%)</td>
<td>163 (40.6%)</td>
<td>224 (56.4%)</td>
<td>158 (40.2%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>(35.8, 45.6)</td>
<td>(51.4, 61.4)</td>
<td>(35.3, 45.2)</td>
</tr>
<tr>
<td>No. of complete response (%)</td>
<td>8 (2.0%)</td>
<td>11 (2.8%)</td>
<td>3 (0.8%)</td>
</tr>
<tr>
<td>No. of partial response (%)</td>
<td>155 (38.7%)</td>
<td>213 (53.7%)</td>
<td>155 (39.4%)</td>
</tr>
<tr>
<td><strong>Investigator-assessed DOR</strong>&lt;sup&gt;*&lt;/sup&gt; (RECIST v1.1)</td>
<td>n = 163</td>
<td>n = 224</td>
<td>n = 158</td>
</tr>
<tr>
<td>Median in months</td>
<td>8.3</td>
<td>11.5</td>
<td>6.0</td>
</tr>
<tr>
<td>95% CI</td>
<td>(7.1, 11.8)</td>
<td>(8.9, 15.7)</td>
<td>(5.5, 6.9)</td>
</tr>
</tbody>
</table>

<sup>a</sup> Primary efficacy endpoints were PFS and OS and they were analysed in the ITT-wild-type (WT) population, i.e. excluding patients with EGFR mutations or ALK rearrangements.

<sup>1</sup> Based on the stratified log-rank test

<sup>2</sup> For informational purposes; in the ITT population, comparisons between Arm B and Arm C as well as between Arm A and Arm C were not formally tested yet as per the pre-specified analysis hierarchy.

<sup>3</sup> Overall best response for complete response and partial response.

<sup>v</sup> Stratified by sex, presence of liver metastases and PD-L1 tumour expression on TC and IC.

<sup>^</sup> The Arm C is the comparison group for all hazard ratios.

<sup>*</sup> Updated PFS analysis and interim OS analysis at clinical cut-off 22 January 2018.

PFS = progression-free survival; RECIST = Response Evaluation Criteria in Solid Tumours v1.1.

CI = confidence interval; DOR = duration of response; OS = overall survival.
Table 10: Summary of updated efficacy for Arm A vs. Arm B in the ITT population (IMpower150)

<table>
<thead>
<tr>
<th>Efficacy endpoint</th>
<th>Arm A (Atezolizumab + Paclitaxel + Carboplatin)</th>
<th>Arm B (Atezolizumab + Bevacizumab + Paclitaxel + Carboplatin)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigator-assessed PFS (RECIST v1.1)*</td>
<td>n = 402</td>
<td>n = 400</td>
</tr>
<tr>
<td>No. of events (%)</td>
<td>330 (82.1%)</td>
<td>291 (72.8%)</td>
</tr>
<tr>
<td>Median duration of PFS (months)</td>
<td>6.7</td>
<td>8.4</td>
</tr>
<tr>
<td>95% CI</td>
<td>(5.7, 6.9)</td>
<td>(8.0, 9.9)</td>
</tr>
<tr>
<td>Stratified hazard ratio‡ (95% CI)</td>
<td>0.67 (0.57, 0.79)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>p-value1,2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

OS interim analysis*  
| No. of deaths (%) | 206 (51.2%) | 192 (48.0%) |
| Median time to events (months) | 19.5 | 19.8 |
| 95% CI | (16.3, 21.3) | (17.4, 24.2) |
| Stratified hazard ratio‡ (95% CI) | 0.90 (0.74, 1.10) | 0.3000 |
| p-value1,2 | | |

1 Based on the stratified log-rank test  
2 For informational purposes; in the ITT population, comparisons between Arm A and Arm B were not included in the pre-specified analysis hierarchy  
‡ Stratified by sex, presence of liver metastases and PD-L1 expression on TC and IC  
* Updated PFS analysis and interim OS analysis at clinical cut-off 22 January 2018  
^ The Arm A is the comparison group for all hazard ratios

Figure 4: Kaplan-Meier curve for overall survival in the ITT population (IMpower150)
Figure 5: Forest plot of overall survival by PD-L1 expression in the ITT population, Arm B vs. C (IMpower150)

<table>
<thead>
<tr>
<th>PD-L1 Expression Level</th>
<th>n (%)</th>
<th>Hazard Ratio</th>
<th>Median OS, (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC ≥ 50% or IC ≥ 10%</td>
<td>148 (19)</td>
<td>0.67</td>
<td>Tecentriq + bevacizumab + paclitaxel + carboplatin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bevacizumab + paclitaxel + carboplatin</td>
</tr>
<tr>
<td>TC or IC ≥ 5%</td>
<td>273 (34)</td>
<td>0.78</td>
<td></td>
</tr>
<tr>
<td>TC or IC ≥ 1%</td>
<td>404 (51)</td>
<td>0.73</td>
<td></td>
</tr>
<tr>
<td>TC and IC &lt; 1%</td>
<td>396 (50)</td>
<td>0.62</td>
<td></td>
</tr>
<tr>
<td>ITT</td>
<td>800 (100)</td>
<td>0.77</td>
<td></td>
</tr>
</tbody>
</table>

* Unstratified hazard ratio

Figure 6: Kaplan-Meier curve for PFS in the ITT population (IMpower150)

<table>
<thead>
<tr>
<th>Treatment arms</th>
<th>Median PFS (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tecentriq + bevacizumab + paclitaxel + carboplatin</td>
<td>14.0 (12.0, 16.0)</td>
<td>0.001</td>
</tr>
<tr>
<td>Bevacizumab + paclitaxel + carboplatin</td>
<td>6.8 (5.9, 7.6)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Figure 7: Forest plot of progression free survival by PD-L1 expression in the ITT population, Arm B vs. C (IMpower150)

<table>
<thead>
<tr>
<th>PD-L1 Expression Level</th>
<th>n (%)</th>
<th>Hazard Ratio</th>
<th>Median PFS, (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC ≥ 50% or IC ≥ 10%</td>
<td>148 (19)</td>
<td>0.33</td>
<td>Tecentriq + bevacizumab + paclitaxel + carboplatin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bevacizumab + paclitaxel + carboplatin</td>
</tr>
<tr>
<td>TC or IC ≥ 5%</td>
<td>273 (34)</td>
<td>0.43</td>
<td></td>
</tr>
<tr>
<td>TC or IC ≥ 1%</td>
<td>404 (51)</td>
<td>0.47</td>
<td></td>
</tr>
<tr>
<td>TC and IC &lt; 1%</td>
<td>396 (50)</td>
<td>0.74</td>
<td></td>
</tr>
<tr>
<td>ITT</td>
<td>800 (100)</td>
<td>0.56</td>
<td></td>
</tr>
</tbody>
</table>

* Unstratified hazard ratio.
In Arm B as compared to Arm C, pre-specified subgroup analyses from the interim OS analysis showed an OS improvement for patients with EGFR mutations or ALK rearrangements (hazard ratio [HR] of 0.54, 95% CI: 0.29, 1.03; median OS not reached vs. 17.5 months), and liver metastases (HR of 0.52, 95% CI: 0.33, 0.82; median OS 13.3 vs. 9.4 months). PFS improvements were also shown in patients with EGFR mutations or ALK rearrangements (HR of 0.55, 95% CI: 0.35, 0.87; median PFS 10.0 vs. 6.1 months) and liver metastases (HR of 0.41, 95% CI: 0.26, 0.62; median PFS 8.2 vs. 5.4 months). OS results were similar for patients aged < 65 and ≥ 65 subgroups, respectively. Data for patients ≥ 75 years of age are too limited to draw conclusions on this population. For all subgroup analyses, formal statistical testing was not planned.

**IMpower130 (GO29537): Randomised phase III trial in chemotherapy-naïve patients with metastatic non-squamous NSCLC, in combination with nab-paclitaxel and carboplatin**

A phase III, open-label, randomised study, GO29537 (IMpower130), was conducted to evaluate the efficacy and safety of atezolizumab in combination with nab-paclitaxel and carboplatin, in chemotherapy-naïve patients with metastatic non-squamous NSCLC. Patients with EGFR mutations or ALK rearrangements should have been previously treated with tyrosine kinase inhibitors.

Patients were staged according to the American Joint Committee on Cancer (AJCC) 7th edition. Patients were excluded if they had a history of autoimmune disease, administration of live, attenuated vaccine within 28 days prior to randomisation, administration of immunostimulatory agents within 4 weeks or systemic immunosuppressive medicinal products within 2 weeks prior to randomisation, and active or untreated CNS metastases. Patients who had prior treatment with CD137 agonists or immune checkpoint blockade therapies (anti-PD-1, and anti-PD-L1 therapeutic antibodies) were not eligible. However, patients who had prior anti-CTLA-4 treatment could be enrolled, as long as the last dose was received at least 6 weeks prior to randomisation, and there was no history of severe immune-mediated adverse events from anti-CTLA-4 (NCI CTCAE Grades 3 and 4). Tumour assessments were conducted every 6 weeks for the first 48 weeks following Cycle 1, then every 9 weeks thereafter. Tumour specimens were evaluated for PD-L1 expression on tumour cells (TC) and tumour infiltrating immune cells (IC) and the results were used to define the PD-L1 expression subgroups for the analyses described below.

Patients, including those with EGFR mutations or ALK rearrangements, were enrolled and were randomised in a 2:1 ratio to receive one of the treatment regimens described in Table 11. Randomisation was stratified by sex, presence of liver metastases and PD-L1 expression on TC and IC. Patients receiving treatment regimen B were able to crossover and receive atezolizumab monotherapy following disease progression.

**Table 11: Intravenous treatment regimens (IMpower130)**

<table>
<thead>
<tr>
<th>Treatment Regimen</th>
<th>Induction (Four or six 21-day cycles)</th>
<th>Maintenance (21-day cycles)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Atezolizumab (1 200 mg)(^a) + nab-paclitaxel (100 mg/m(^2))(^bc) + carboplatin (AUC 6)(^c)</td>
<td>Atezolizumab (1 200 mg)(^a)</td>
</tr>
<tr>
<td>B</td>
<td>Nab-paclitaxel (100 mg/m(^2))(^bc) + carboplatin (AUC 6)(^c)</td>
<td>Best supportive care or pemetrexed</td>
</tr>
</tbody>
</table>

\(^a\) Atezolizumab is administered until loss of clinical benefit as assessed by investigator  
\(^b\) Nab-paclitaxel is administered on days 1, 8, and 15 of each cycle  
\(^c\) Nab-paclitaxel and carboplatin are administered until completion of 4-6 cycles, or progressive disease or unacceptable toxicity whichever occurs first
The demographics and baseline disease characteristics of the study population defined as ITT-WT (n=679) were well balanced between the treatment arms. The median age was 64 years (range: 18 to 86 years). The majority of the patients were male (59%) and white (90%). Fourteen point seven percent of patients had liver metastases at baseline, and most patients were current or previous smokers (90%). The majority of patients had a baseline ECOG performance status of 1 (59%) and PD-L1 expression < 1% (approximately 52%). Among 107 Arm B patients who had a response status of stable disease, partial response, or complete response after induction therapy, 40 received pemetrexed switch maintenance therapy.

The primary analysis was conducted in all patients, excluding those with EGFR mutations or ALK rearrangements, defined as ITT-WT population (n=679). Patients had a median survival follow up time of 18.6 months and showed improved OS and PFS with atezolizumab, nab-paclitaxel and carboplatin as compared to the control. The key results are summarised in Table 12 and Kaplan-Meier curves for OS and PFS are presented in Figures 8 and 10, respectively. The exploratory results of OS and PFS by PD-L1 expression are summarised in Figures 9 and 11, respectively. Patients with liver metastases did not show improved PFS or OS with atezolizumab, nab-paclitaxel and carboplatin, compared to nab-paclitaxel and carboplatin (HR of 0.93, 95% CI: 0.59, 1.47 for PFS and HR of 1.04, 95% CI: 0.63, 1.72 for OS, respectively).

Fifty-nine percent of patients in the nab-paclitaxel and carboplatin arm received any cancer immunotherapy after disease progression, which includes atezolizumab as crossover treatment (41% of all patients), compared to 7.3% of patients in the atezolizumab, nab-paclitaxel and carboplatin arm.

In an exploratory analysis with longer follow up (median: 24.1 months), the median OS for both arms was unchanged relative to the primary analysis, with HR = 0.82 (95% CI: 0.67, 1.01).
Table 12: Summary of efficacy from IMpower130 in the primary analysis (ITT-WT population)

<table>
<thead>
<tr>
<th>Efficacy endpoints</th>
<th>Arm A Atezolizumab + nab-paclitaxel + carboplatin</th>
<th>Arm B Nab-paclitaxel + carboplatin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Co-primary endpoints</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>OS</strong></td>
<td>n=451</td>
<td>n=228</td>
</tr>
<tr>
<td>No. of deaths (%)</td>
<td>226 (50.1%)</td>
<td>131 (57.5%)</td>
</tr>
<tr>
<td>Median time to events (months)</td>
<td>18.6</td>
<td>13.9</td>
</tr>
<tr>
<td>95% CI</td>
<td>(16.0, 21.2)</td>
<td>(12.0, 18.7)</td>
</tr>
<tr>
<td>Stratified hazard ratio‡ (95% CI)</td>
<td>0.79 (0.64, 0.98)</td>
<td>0.033</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-month OS (%)</td>
<td>63</td>
<td>56</td>
</tr>
<tr>
<td><strong>Investigator-assessed PFS (RECIST v1.1)</strong></td>
<td>n=451</td>
<td>n=228</td>
</tr>
<tr>
<td>No. of events (%)</td>
<td>347 (76.9%)</td>
<td>198 (86.8%)</td>
</tr>
<tr>
<td>Median duration of PFS (months)</td>
<td>7.0</td>
<td>5.5</td>
</tr>
<tr>
<td>95% CI</td>
<td>(6.2, 7.3)</td>
<td>(4.4, 5.9)</td>
</tr>
<tr>
<td>Stratified hazard ratio‡ (95% CI)</td>
<td>0.64 (0.54, 0.77)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-month PFS (%)</td>
<td>29%</td>
<td>14%</td>
</tr>
<tr>
<td><strong>Other endpoints</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Investigator-assessed ORR (RECIST v1.1)^</strong></td>
<td>n=447</td>
<td>n=226</td>
</tr>
<tr>
<td>No. of confirmed responders (%)</td>
<td>220 (49.2%)</td>
<td>72 (31.9%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>(44.5, 54.0)</td>
<td>(25.8, 38.4)</td>
</tr>
<tr>
<td>No. of complete response (%)</td>
<td>11 (2.5%)</td>
<td>3 (1.3%)</td>
</tr>
<tr>
<td>No. of partial response (%)</td>
<td>209 (46.8%)</td>
<td>69 (30.5%)</td>
</tr>
<tr>
<td><strong>Investigator-assessed confirmed DOR (RECIST 1.1)^</strong></td>
<td>n=220</td>
<td>n=72</td>
</tr>
<tr>
<td>Median in months</td>
<td>8.4</td>
<td>6.1</td>
</tr>
<tr>
<td>95% CI</td>
<td>(6.9, 11.8)</td>
<td>(5.5, 7.9)</td>
</tr>
</tbody>
</table>

‡ Stratified by sex and PD-L1 expression on TC and IC
^ Confirmed ORR and DoR are exploratory endpoints
PFS=progression-free survival; RECIST=Response Evaluation Criteria in Solid Tumours v1.1.; CI=confidence interval; ORR=objective response rate; DOR=duration of response; OS=overall survival
Figure 8: Kaplan-Meier curves for overall survival (IMpower130)

Figure 9: Forest plot of overall survival by PD-L1 expression (IMpower130)
A phase III, open-label, multi-centre, randomised study, IMpower110, was conducted to evaluate the efficacy and safety of atezolizumab in chemotherapy-naïve patients with metastatic NSCLC. Patients had PD-L1 expression ≥ 1% TC (PD-L1 stained ≥ 1% of tumour cells) or ≥ 1% IC (PD-L1 stained tumour-infiltrating immune cells covering ≥ 1% of the tumour area) based on the VENTANA PD-L1 (SP142) Assay.

A total of 572 patients were randomised in a 1:1 ratio to receive atezolizumab (Arm A) or chemotherapy (Arm B). Atezolizumab was administered as a fixed dose of 1 200 mg by intravenous infusion every 3 weeks until loss of clinical benefit as assessed by the investigator or unacceptable toxicity. The chemotherapy regimens are described in Table 13. Randomisation was stratified by sex, ECOG performance status, histology, and PD-L1 tumour expression on TC and IC.
## Table 13: Chemotherapy intravenous treatment regimens (IMpower110)

<table>
<thead>
<tr>
<th>Treatment regimen</th>
<th>Induction (Four or Six 21-day cycles)</th>
<th>Maintenance (21-day cycles)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B (Non-squamous)</td>
<td>Cisplatin&lt;sup&gt;a&lt;/sup&gt; (75 mg/m²) + pemetrexed&lt;sup&gt;a&lt;/sup&gt; (500 mg/m²) OR carboplatin&lt;sup&gt;a&lt;/sup&gt;(AUC 6) + pemetrexed&lt;sup&gt;a&lt;/sup&gt; (500 mg/m²)</td>
<td>Pemetrexed&lt;sup&gt;b,d&lt;/sup&gt; (500 mg/m²)</td>
</tr>
<tr>
<td>B (Squamous)</td>
<td>Cisplatin&lt;sup&gt;a&lt;/sup&gt; (75 mg/m²) + gemcitabine&lt;sup&gt;c&lt;/sup&gt; (1 250 mg/m²) OR carboplatin&lt;sup&gt;a&lt;/sup&gt;(AUC 5) + gemcitabine&lt;sup&gt;c&lt;/sup&gt; (1 000 mg/m²)</td>
<td>Best supportive care&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>Cisplatin, carboplatin, pemetrexed and gemcitabine are administered until completion of 4 or 6 cycles, or progressive disease, or unacceptable toxicity

<sup>b</sup>Pemetrexed is administered as maintenance regimen every 21 days until progressive disease or unacceptable toxicity

<sup>c</sup>Gemcitabine is administered on days 1 and 8 of each cycle

<sup>d</sup>No crossover was allowed from the control arm (platinum-based chemotherapy) to the atezolizumab arm (Arm A)

Patients were excluded if they had a history of autoimmune disease; administration of a live, attenuated vaccine within 28 days prior to randomisation, administration of systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medicinal products within 2 weeks prior to randomisation, active or untreated CNS metastases. Tumour assessments were conducted every 6 weeks for the first 48 weeks following Cycle 1, Day 1 and then every 9 weeks thereafter.

The demographics and baseline disease characteristics in patients with PD-L1 expression ≥ 1% TC or ≥ 1% IC who do not have EGFR mutations or ALK rearrangements (n=554) were well balanced between the treatment arms. The median age was 64.5 years (range: 30 to 87), and 70% of patients were male. The majority of patients were white (84%) and Asian (14%). Most patients were current or previous smokers (87%) and baseline ECOG performance status in patients was 0 (36%) or 1 (64%). Overall, 69% of patients had non-squamous disease and 31% of patients had squamous disease. The demographics and baseline disease characteristics in patients with high PD-L1 expression (PD-L1 ≥ 50% TC or ≥ 10% IC) who do not have with EGFR mutations or ALK rearrangements (n=205) were generally representative of the broader study population and were balanced between the treatment arms.

The primary endpoint was overall survival (OS). At the time of the interim OS analysis, patients with high PD-L1 expression excluding those with EGFR mutations or ALK rearrangements (n=205) showed statistically significant improvement in OS for the patients randomised to atezolizumab (Arm A) as compared with chemotherapy (Arm B) (HR of 0.59, 95% CI: 0.40, 0.89; median OS of 20.2 months vs 13.1 months) with a two-sided p-value of 0.0106. The median survival follow-up time in patients with high PD-L1 expression was 15.7 months.

In an exploratory OS analysis with longer follow up (median: 31.3 months) for these patients, the median OS for the atezolizumab arm was unchanged relative to the primary OS interim analysis (20.2 months) and was 14.7 months for the chemotherapy arm (HR of 0.76, 95% CI: 0.54, 1.09). The key results at the exploratory analysis are summarised in Table 14. The Kaplan-Meier curves for OS and PFS in patients with high PD-L1 expression are presented in Figures 12 and 13. A higher proportion of patients experienced death within the first 2.5 months in the atezolizumab arm (16/107, 15.0%) as compared to the chemotherapy arm (10/98, 10.2%). No specific factor(s) associated with early deaths could be identified.
Table 14: Summary of efficacy in patients with high PD-L1 expression ≥ 50% TC or ≥ 10% IC (IMpower110)

<table>
<thead>
<tr>
<th>Efficacy endpoints</th>
<th>Arm A (Atezolizumab)</th>
<th>Arm B (Chemotherapy)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary endpoint</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall survival</td>
<td>n = 107</td>
<td>n = 98</td>
</tr>
<tr>
<td>No. of deaths (%)</td>
<td>64 (59.8%)</td>
<td>64 (65.3%)</td>
</tr>
<tr>
<td>Median time to events (months)</td>
<td>20.2</td>
<td>14.7</td>
</tr>
<tr>
<td>95% CI</td>
<td>(17.2, 27.9)</td>
<td>(7.4, 17.7)</td>
</tr>
<tr>
<td>Stratified hazard ratio‡ (95% CI)</td>
<td>0.76 (0.54, 1.09)</td>
<td></td>
</tr>
<tr>
<td>12-month OS (%)</td>
<td>66.1</td>
<td>52.3</td>
</tr>
<tr>
<td><strong>Secondary endpoints</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigator-assessed PFS (RECIST v1.1)</td>
<td>n = 107</td>
<td>n = 98</td>
</tr>
<tr>
<td>No. of events (%)</td>
<td>82 (76.6%)</td>
<td>87 (88.8%)</td>
</tr>
<tr>
<td>Median duration of PFS (months)</td>
<td>8.2</td>
<td>5.0</td>
</tr>
<tr>
<td>95% CI</td>
<td>(6.8, 11.4)</td>
<td>(4.2, 5.7)</td>
</tr>
<tr>
<td>Stratified hazard ratio‡ (95% CI)</td>
<td>0.59 (0.43, 0.81)</td>
<td></td>
</tr>
<tr>
<td>12-month PFS (%)</td>
<td>39.2</td>
<td>19.2</td>
</tr>
<tr>
<td>Investigator-assessed ORR (RECIST 1.1)</td>
<td>n = 107</td>
<td>n = 98</td>
</tr>
<tr>
<td>No. of responders (%)</td>
<td>43 (40.2%)</td>
<td>28 (28.6%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>(30.8, 50.1)</td>
<td>(19.9, 38.6)</td>
</tr>
<tr>
<td>No. of complete response (%)</td>
<td>1 (0.9%)</td>
<td>2 (2.0%)</td>
</tr>
<tr>
<td>No. of partial response (%)</td>
<td>42 (39.3%)</td>
<td>26 (26.5%)</td>
</tr>
<tr>
<td>Investigator-assessed DOR (RECIST 1.1)</td>
<td>n = 43</td>
<td>n = 28</td>
</tr>
<tr>
<td>Median in months</td>
<td>38.9</td>
<td>8.3</td>
</tr>
<tr>
<td>95% CI</td>
<td>(16.1, NE)</td>
<td>(5.6, 11.0)</td>
</tr>
</tbody>
</table>

‡ Stratified by sex and ECOG performance status (0 vs. 1)
PFS = progression-free survival; RECIST = Response Evaluation Criteria in Solid Tumours v1.1; CI = confidence interval; ORR = objective response rate; DOR = duration of response; OS = overall survival; NE = not estimable.
The observed OS improvement in the atezolizumab arm compared with the chemotherapy arm was consistently shown across subgroups in patients with high PD-L1 expression including both non-squamous NSCLC patients (hazard ratio [HR] of 0.62, 95% CI: 0.40, 0.96; median OS 20.2 vs. 10.5 months) and squamous NSCLC patients (HR of 0.56, 95% CI: 0.23, 1.37; median OS not reached vs. 15.3 months). Data for patients ≥ 75 years of age and patients who were never smokers are too limited to draw conclusions in these subgroups.
Second-line treatment of NSCLC

OAK (GO28915): Randomised phase III trial in locally advanced or metastatic NSCLC patients previously treated with chemotherapy

A phase III, open-label, multi-centre, international, randomised study, OAK, was conducted to evaluate the efficacy and safety of atezolizumab compared with docetaxel in patients with locally advanced or metastatic NSCLC who progressed during or following a platinum-containing regimen. This study excluded patients who had a history of autoimmune disease, active or corticosteroid-dependent brain metastases, administration of a live, attenuated vaccine within 28 days prior to enrolment, administration of systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medicinal product within 2 weeks prior to enrolment. Tumour assessments were conducted every 6 weeks for the first 36 weeks, and every 9 weeks thereafter. Tumour specimens were evaluated prospectively for PD-L1 expression on tumour cells (TC) and tumour-infiltrating immune cells (IC).

A total of 1 225 patients were enrolled and per the analysis plan the first 850 randomised patients were included in the primary efficacy analysis. Randomisation was stratified by PD-L1 expression status on IC, by the number of prior chemotherapy regimens, and by histology. Patients were randomised (1:1) to receive either atezolizumab or docetaxel.

Atezolizumab was administered as a fixed dose of 1 200 mg by intravenous infusion every 3 weeks. No dose reduction was allowed. Patients were treated until loss of clinical benefit as assessed by the investigator. Docetaxel was administered 75 mg/m² by intravenous infusion on day 1 of each 3-week cycle until disease progression. For all treated patients, the median duration of treatment was 2.1 months for the docetaxel arm and 3.4 months for the atezolizumab arm.

The demographic and baseline disease characteristics of the primary analysis population were well balanced between the treatment arms. The median age was 64 years (range: 33 to 85), and 61% of patients were male. The majority of patients were white (70%). Approximately three-quarters of patients had non-squamous histology (74%), 10% had known EGFR mutation, 0.2% had known ALK rearrangements, 10% had CNS metastases at baseline, and most patients were current or previous smokers (82%). Baseline ECOG performance status was 0 (37%) or 1 (63%). Seventy-five percent of patients received only one prior platinum-based therapeutic regimen.

The primary efficacy endpoint was OS. The key results of this study with a median survival follow-up of 21 months are summarised in Table 15. Kaplan-Meier curves for OS in the ITT population are presented in Figure 14. Figure 15 summarises the results of OS in the ITT and PD-L1 subgroups, demonstrating OS benefit with atezolizumab in all subgroups, including those with PD-L1 expression < 1% in TC and IC.
Table 15: Summary of efficacy in the primary analysis population (all comers)* (OAK)

<table>
<thead>
<tr>
<th>Efficacy endpoint</th>
<th>Atezolizumab (n = 425)</th>
<th>Docetaxel (n = 425)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary efficacy endpoint</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>OS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of deaths (%)</td>
<td>271 (64%)</td>
<td>298 (70%)</td>
</tr>
<tr>
<td>Median time to events (months)</td>
<td>13.8</td>
<td>9.6</td>
</tr>
<tr>
<td>95% CI</td>
<td>(11.8, 15.7)</td>
<td>(8.6, 11.2)</td>
</tr>
<tr>
<td>Stratified‡ hazard ratio (95% CI)</td>
<td>0.73 (0.62, 0.87)</td>
<td>0.95 (0.82, 1.10)</td>
</tr>
<tr>
<td>p-value**</td>
<td>0.003</td>
<td></td>
</tr>
<tr>
<td>12-month OS (%)***</td>
<td>218 (55%)</td>
<td>151 (41%)</td>
</tr>
<tr>
<td>18-month OS (%)***</td>
<td>157 (40%)</td>
<td>98 (27%)</td>
</tr>
<tr>
<td><strong>Secondary endpoints</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigator-assessed PFS (RECIST v1.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of events (%)</td>
<td>380 (89%)</td>
<td>375 (88%)</td>
</tr>
<tr>
<td>Median duration of PFS (months)</td>
<td>2.8</td>
<td>4.0</td>
</tr>
<tr>
<td>95% CI</td>
<td>(2.6, 3.0)</td>
<td>(3.3, 4.2)</td>
</tr>
<tr>
<td>Stratified hazard ratio (95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigator-assessed ORR (RECIST v1.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of responders (%)</td>
<td>58 (14%)</td>
<td>57 (13%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>(10.5, 17.3)</td>
<td>(10.3, 17.0)</td>
</tr>
<tr>
<td>Investigator-assessed DOR (RECIST v1.1)</td>
<td>n = 58</td>
<td>n = 57</td>
</tr>
<tr>
<td>Median in months</td>
<td>16.3</td>
<td>6.2</td>
</tr>
<tr>
<td>95% CI</td>
<td>(10.0, NE)</td>
<td>(4.9, 7.6)</td>
</tr>
</tbody>
</table>

CI = confidence interval; DOR = duration of response; NE = not estimable; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; RECIST = Response Evaluation Criteria in Solid Tumours v1.1.

* The primary analysis population consists of the first 850 randomised patients
‡ Stratified by PD-L1 expression in tumour infiltrating immune cells, the number of prior chemotherapy regimens, and histology
** Based on the stratified log-rank test
*** Based on Kaplan-Meier estimates
An improvement in OS was observed with atezolizumab compared to docetaxel in both non-squamous NSCLC patients (hazard ratio [HR] of 0.73, 95% CI: 0.60, 0.89; median OS of 15.6 vs. 11.2 months for atezolizumab and docetaxel, respectively) and squamous NSCLC patients (HR of 0.73, 95% CI: 0.54, 0.98; median OS of 8.9 vs. 7.7 months for atezolizumab and docetaxel, respectively). The observed OS improvement was consistently demonstrated across subgroups of patients including those with brain metastases at baseline (HR of 0.54, 95% CI: 0.31, 0.94; median OS of 20.1 vs. 11.9 months for atezolizumab and docetaxel, respectively) and patients who were never smokers (HR of 0.71, 95% CI: 0.47, 1.08; median OS of 16.3 vs. 12.6 months for atezolizumab and docetaxel, respectively). However, patients with EGFR mutations did not show improved OS with atezolizumab compared to docetaxel (HR of 1.24, 95% CI: 0.71, 2.18; median OS of 10.5 vs. 16.2 months for atezolizumab and docetaxel, respectively).

*a Stratified HR for ITT and TC or IC ≥ 1%. Unstratified HR for other exploratory subgroups.
Prolonged time to deterioration of patient-reported pain in chest as measured by the EORTC QLQ-LC13 was observed with atezolizumab compared to docetaxel (HR of 0.71, 95% CI: 0.49, 1.05; median not reached in either arm). The time to deterioration in other lung cancer symptoms (i.e. cough, dyspnoea, and arm/shoulder pain) as measured by the EORTC QLQ-LC13 was similar between atezolizumab and docetaxel. These results should be interpreted with caution due to the open-label design of the study.

**POPLAR (GO28753): Randomised phase II trial in locally advanced or metastatic NSCLC patients previously treated with chemotherapy**

A phase II, multi-centre, international, randomised, open-label, controlled study, POPLAR, was conducted in patients with locally advanced or metastatic NSCLC who progressed during or following a platinum-containing regimen, regardless of PD-L1 expression. The primary efficacy outcome was overall survival. A total of 287 patients were randomised 1:1 to receive either atezolizumab (1 200 mg by intravenous infusion every 3 weeks until loss of clinical benefit) or docetaxel (75 mg/m² by intravenous infusion on day 1 of each 3-week cycle until disease progression). Randomisation was stratified by PD-L1 expression status on IC, by the number of prior chemotherapy regimens and by histology. An updated analysis with a total of 200 deaths observed and a median survival follow-up of 22 months showed a median OS of 12.6 months in patients treated with atezolizumab, vs. 9.7 months in patients treated with docetaxel (HR of 0.69, 95% CI: 0.52, 0.92). ORR was 15.3% vs. 14.7% and median DOR was 18.6 months vs. 7.2 months for atezolizumab vs. docetaxel, respectively.

**Small cell lung cancer**

**IMpower133 (GO30081): Randomised phase I/III trial in patients with chemotherapy-naïve extensive-stage SCLC, in combination with carboplatin and etoposide**

A Phase I/III, randomised, multicentre, double-blind, placebo-controlled study, IMpower133, was conducted to evaluate the efficacy and safety of atezolizumab in combination with carboplatin and etoposide in patients with chemotherapy-naïve ES-SCLC.

Patients were excluded if they had active or untreated CNS metastases; history of autoimmune disease; administration of live, attenuated vaccine within 4 weeks prior to randomisation; administration of systemic immunosuppressive medicinal products within 1 week prior to randomisation. Tumour assessments were conducted every 6 weeks for the first 48 weeks following Cycle 1, Day 1 and then every 9 weeks thereafter. Patients who met established criteria and who agreed to be treated beyond disease progression had tumour assessments conducted every 6 weeks until treatment discontinuation.

A total of 403 patients were enrolled and randomised (1:1) to receive one of the treatment regimens described in Table 16. Randomisation was stratified by sex, ECOG performance status, and presence of brain metastases.
Table 16: Intravenous treatment regimens (IMpower133)

<table>
<thead>
<tr>
<th>Treatment Regimen</th>
<th>Induction (Four 21-Day Cycles)</th>
<th>Maintenance (21-Day Cycles)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>atezolizumab (1 200 mg)&lt;sup&gt;a&lt;/sup&gt; + carboplatin (AUC 5)&lt;sup&gt;b&lt;/sup&gt; + etoposide (100 mg/m&lt;sup&gt;2&lt;/sup&gt;)&lt;sup&gt;b,c&lt;/sup&gt;</td>
<td>atezolizumab (1 200 mg)&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>B</td>
<td>placebo + carboplatin (AUC 5)&lt;sup&gt;b&lt;/sup&gt; + etoposide (100 mg/m&lt;sup&gt;2&lt;/sup&gt;)&lt;sup&gt;b,c&lt;/sup&gt;</td>
<td>placebo</td>
</tr>
</tbody>
</table>

<sup>a</sup> Atezolizumab was administered until loss of clinical benefit as assessed by investigator

<sup>b</sup> Carboplatin and etoposide were administered until completion of 4 cycles, or progressive disease or unacceptable toxicity, whichever occurs first

<sup>c</sup> Etoposide was administered on day 1, 2 and 3 of each cycle

The demographic and baseline disease characteristics of the study population were well balanced between the treatment arms. The median age was 64 years (range: 26 to 90 years) with 10% of patients ≥ 75 years of age. The majority of patients were male (65%), white (80%), and 9% had brain metastases and most patients were current or previous smokers (97%). Baseline ECOG performance status was 0 (35%) or 1 (65%).

At the time of the primary analysis, patients had a median survival follow up time of 13.9 months. A statistically significant improvement in OS was observed with atezolizumab in combination with carboplatin and etoposide compared to the control arm (HR of 0.70, 95% CI: 0.54, 0.91; median OS of 12.3 months vs. 10.3 months). In the exploratory OS final analysis with longer follow up (median: 22.9 months), the median OS for both arms was unchanged relative to the primary OS interim analysis. The PFS, ORR and DOR results from the primary analysis as well as the exploratory OS final analysis results are summarised in Table 17. Kaplan-Meier curves for OS and PFS are presented in Figures 16 and 17. Data for patients with brain metastases are too limited to draw conclusions on this population.
Table 17: Summary of efficacy (IMpower133)

<table>
<thead>
<tr>
<th>Key efficacy endpoints</th>
<th>Arm A (Atezolizumab + carboplatin + etoposide)</th>
<th>Arm B (Placebo + carboplatin + etoposide)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Co-primary endpoints</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>OS analysis</strong>*</td>
<td>n=201</td>
<td>n=202</td>
</tr>
<tr>
<td>No. of deaths (%)</td>
<td>142 (70.6%)</td>
<td>160 (79.2%)</td>
</tr>
<tr>
<td>Median time to events (months)</td>
<td>12.3</td>
<td>10.3</td>
</tr>
<tr>
<td>95% CI</td>
<td>(10.8, 15.8)</td>
<td>(9.3, 11.3)</td>
</tr>
<tr>
<td>Stratified hazard ratio‡ (95% CI)</td>
<td>0.76 (0.60, 0.95)</td>
<td>0.0154***</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-month OS (%)</td>
<td>51.9</td>
<td>39.0</td>
</tr>
<tr>
<td><strong>Investigator-assessed PFS (RECIST v1.1)</strong></td>
<td>n=201</td>
<td>n=202</td>
</tr>
<tr>
<td>No. of events (%)</td>
<td>171 (85.1%)</td>
<td>189 (93.6%)</td>
</tr>
<tr>
<td>Median duration of PFS (months)</td>
<td>5.2</td>
<td>4.3</td>
</tr>
<tr>
<td>95% CI</td>
<td>(4.4, 5.6)</td>
<td>(4.2, 4.5)</td>
</tr>
<tr>
<td>Stratified hazard ratio‡ (95% CI)</td>
<td>0.77 (0.62, 0.96)</td>
<td>0.0170</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6-month PFS (%)</td>
<td>30.9</td>
<td>22.4</td>
</tr>
<tr>
<td>12-month PFS (%)</td>
<td>12.6</td>
<td>5.4</td>
</tr>
<tr>
<td>Other endpoints</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Investigator-assessed ORR (RECIST 1.1)</strong>^</td>
<td>n=201</td>
<td>n=202</td>
</tr>
<tr>
<td>No. of responders (%)</td>
<td>121 (60.2%)</td>
<td>130 (64.4%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>(53.1, 67.0)</td>
<td>(57.3, 71.0)</td>
</tr>
<tr>
<td>No. of complete response (%)</td>
<td>5 (2.5%)</td>
<td>2 (1.0%)</td>
</tr>
<tr>
<td>No. of partial response (%)</td>
<td>116 (57.7%)</td>
<td>128 (63.4%)</td>
</tr>
<tr>
<td><strong>Investigator-assessed DOR (RECIST 1.1)</strong>^</td>
<td>n =121</td>
<td>n = 130</td>
</tr>
<tr>
<td>Median in months</td>
<td>4.2</td>
<td>3.9</td>
</tr>
<tr>
<td>95% CI</td>
<td>(4.1, 4.5)</td>
<td>(3.1, 4.2)</td>
</tr>
</tbody>
</table>

PFS=progression-free survival; RECIST=Response Evaluation Criteria in Solid Tumours v1.1.; CI=confidence interval; ORR=objective response rate; DOR=duration of response; OS=overall survival

‡ Stratified by sex and ECOG performance status

* Exploratory OS final analysis at clinical cut-off 24 January 2019

** PFS, ORR and DOR analyses at clinical cut-off 24 April 2018

*** For descriptive purposes only

^ Confirmed ORR and DoR are exploratory endpoints
Figure 16: Kaplan-Meier curve for overall survival (IMpower133)

<table>
<thead>
<tr>
<th>Treatment arm</th>
<th>Median OS</th>
<th>HR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tecentriq+carboplatin+etoposide</td>
<td>12.3 mo</td>
<td>0.70</td>
<td>0.0154</td>
</tr>
<tr>
<td>Placebo+carboplatin+etoposide</td>
<td>10.3 mo</td>
<td>(0.69, 0.95)</td>
<td></td>
</tr>
</tbody>
</table>

No. at Risk
Tecentriq+carboplatin+etoposide: 201 190 178 158 147 98 48 41 32 29 25 17 12 11 3 3 2 2 2 1 1
Placebo+carboplatin+etoposide: 202 193 184 167 147 80 44 30 25 23 16 15 9 6 5 3 3

Figure 17: Kaplan-Meier curve for progression-free survival (IMpower133)

<table>
<thead>
<tr>
<th>Treatment arm</th>
<th>Median PFS</th>
<th>HR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tecentriq+carboplatin+etoposide</td>
<td>5.2 mo</td>
<td>0.77</td>
<td>0.0170</td>
</tr>
<tr>
<td>Placebo+carboplatin+etoposide</td>
<td>4.3 mo</td>
<td>(0.82, 0.96)</td>
<td></td>
</tr>
</tbody>
</table>

No. at Risk
Tecentriq+carboplatin+etoposide: 201 190 178 158 147 98 48 41 32 29 25 17 12 11 3 3 2 2 2 1 1
Placebo+carboplatin+etoposide: 202 193 184 167 147 80 44 30 25 23 16 15 9 6 5 3 3
Triple-negative breast cancer

**IMpassion130 (WO29522): Randomised phase III trial in locally advanced or metastatic TNBC patients previously untreated for metastatic disease**

A phase III, double-blind, two-arm, multi-centre, international, randomised, placebo-controlled study, IMpassion130, was conducted to evaluate the efficacy and safety of atezolizumab in combination with nab-paclitaxel, in patients with unresectable locally advanced or metastatic TNBC who had not received prior chemotherapy for metastatic disease. Patients had to be eligible for taxane monotherapy (i.e. absence of rapid clinical progression, life-threatening visceral metastases, or need for rapid symptom and/or disease control) and were excluded if they had received prior chemotherapy in the neoadjuvant or adjuvant setting within the last 12 months, a history of autoimmune disease; administration of a live, attenuated vaccine within 4 weeks prior to randomisation, administration of systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medicinal products within 2 weeks prior to randomisation; untreated, symptomatic or corticosteroid-dependent brain metastases. Tumour assessments were performed every 8 weeks (± 1 week) for the first 12 months after Cycle 1, day 1 and every 12 weeks (± 1 week) thereafter.

A total of 902 patients were enrolled and stratified by presence of liver metastases, prior taxane treatment, and by PD-L1 expression status in tumour-infiltrating immune cells (IC) (PD-L1 stained tumour-infiltrating immune cells [IC] < 1% of tumour area vs. ≥ 1% of the tumour area) assessed by the VENTANA PD-L1 (SP142) Assay.

Patients were randomised to receive atezolizumab 840 mg or placebo by intravenous infusions on days 1 and 15 of every 28-day cycle, plus nab-paclitaxel (100 mg/m²) administered via intravenous infusion on days 1, 8 and 15 of every 28-day cycle. Patients received treatment until radiographic disease progression per RECIST v1.1, or unacceptable toxicity. Treatment with atezolizumab could be continued when nab-paclitaxel was stopped due to unacceptable toxicity. The median number of treatment cycles was 7 for atezolizumab and 6 for nab-paclitaxel in each treatment arm.

The demographic and baseline disease characteristics of the study population were well balanced between the treatment arms. Most patients were women (99.6%), 67.5% were white and 17.8% Asian. The median age was 55 years (range: 20-86). Baseline ECOG performance status was 0 (58.4%) or 1 (41.3%). Overall, 41% of enrolled patients had PD-L1 expression ≥ 1%, 27% had liver metastases and 7% asymptomatic brain metastases at baseline. Approximately half the patients had received a taxane (51%) or anthracycline (54%) in the (neo)adjuvant setting. Patient demographics and baseline tumour disease in patients with PD-L1 expression ≥ 1% were generally representative of the broader study population.

The co-primary efficacy endpoints included investigator-assessed progression free survival (PFS) in the ITT population and in patients with PD-L1 expression ≥ 1% per RECIST v1.1 as well as overall survival (OS) in the ITT population and in patients with PD-L1 expression ≥ 1%. Secondary efficacy endpoints included objective response rate (ORR) and duration of response (DOR) per RECIST v1.1.

PFS, ORR and DOR results of IMpassion130 for patients with PD-L1 expression ≥ 1% at the time of the final analysis for PFS with a median survival follow up of 13 months are summarised in Table 18 with Kaplan-Meier curves for PFS in Figure 18. Patients with PD-L1 expression < 1% did not show improved PFS when atezolizumab was added to nab-paclitaxel (HR of 0.94, 95% CI 0.78, 1.13).

The final OS analysis was performed in patients with PD-L1 expression ≥ 1% with a median follow up of 19.12 months. OS results are presented in Table 18 and Kaplan-Meier curves in Figure 19. Patients with PD-L1 expression < 1% did not show improved OS when atezolizumab was added to nab-paclitaxel (HR of 1.02, 95% CI 0.84, 1.24).

Exploratory subgroup analyses were performed in patients with PD-L1 expression ≥ 1%, exploring prior (neo)adjuvant treatment, BRCA1/2 mutation and asymptomatic brain metastases at baseline.
In patients who had received prior (neo)adjuvant treatment (n=242), the hazard ratio for primary (final) PFS was 0.79 and 0.77 for final OS while in patients who had not received prior (neo)adjuvant treatment (n=127), the hazard ratio for primary (final) PFS was 0.44 and 0.54 for final OS.

In the IMpassion130 study, of the 614 patients tested, 89 (15%) carried pathogenic BRCA1/2 mutations. From the PD-L1+/BRCA1/2 mutant subgroup, 19 patients received atezolizumab plus nab-paclitaxel and 26 placebo plus nab-paclitaxel. Based on exploratory analysis and acknowledging the small sample size, the presence of BRCA1/2 mutation does not seem to impact the PFS clinical benefit of atezolizumab and nab-paclitaxel.

There was no evidence of efficacy in patients with asymptomatic brain metastases at baseline, although the number of patients treated was small; the median PFS was 2.2 months in the atezolizumab plus nab-paclitaxel arm (n=15) compared to 5.6 months in the placebo plus nab-paclitaxel arm (n=11) (HR 1.40; 95% CI 0.57, 3.44).

Table 18: Summary of efficacy in patients with PD-L1 expression ≥1% (IMpassion130)

<table>
<thead>
<tr>
<th>Key efficacy endpoints</th>
<th>Atezolizumab + nab-paclitaxel</th>
<th>Placebo + nab-paclitaxel</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary efficacy endpoints</strong></td>
<td>n=185</td>
<td>n=184</td>
</tr>
<tr>
<td>Investigator-assessed PFS (RECIST v1.1) – Primary analysis³</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of events (%)</td>
<td>138 (74.6%)</td>
<td>157 (85.3%)</td>
</tr>
<tr>
<td>Median duration of PFS (months)</td>
<td>7.5</td>
<td>5.0</td>
</tr>
<tr>
<td>95% CI</td>
<td>(6.7, 9.2)</td>
<td>(3.8, 5.6)</td>
</tr>
<tr>
<td>Stratified hazard ratio‡ (95% CI)</td>
<td>0.62 (0.49, 0.78)</td>
<td></td>
</tr>
<tr>
<td>p-value¹</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>12-month PFS (%)</td>
<td>29.1</td>
<td>16.4</td>
</tr>
<tr>
<td>Investigator-assessed PFS (RECIST v1.1) – Updated exploratory analysis⁴</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of events (%)</td>
<td>149 (80.5%)</td>
<td>163 (88.6%)</td>
</tr>
<tr>
<td>Median duration of PFS (months)</td>
<td>7.5</td>
<td>5.3</td>
</tr>
<tr>
<td>95% CI</td>
<td>(6.7, 9.2)</td>
<td>(3.8, 5.6)</td>
</tr>
<tr>
<td>Stratified hazard ratio‡ (95% CI)</td>
<td>0.63 (0.50-0.80)</td>
<td></td>
</tr>
<tr>
<td>p-value¹</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>12-month PFS (%)</td>
<td>30.3</td>
<td>17.3</td>
</tr>
<tr>
<td>**OS **¹²⁵</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of deaths (%)</td>
<td>120 (64.9%)</td>
<td>139 (75.5%)</td>
</tr>
<tr>
<td>Median time to events (months)</td>
<td>25.4</td>
<td>17.9</td>
</tr>
<tr>
<td>95% CI</td>
<td>(19.6, 30.7)</td>
<td>(13.6, 20.3)</td>
</tr>
<tr>
<td>Stratified hazard ratio‡ (95% CI)</td>
<td>0.67 (0.53, 0.86)</td>
<td></td>
</tr>
</tbody>
</table>
### Key efficacy endpoints

<table>
<thead>
<tr>
<th></th>
<th>Atezolizumab + nab-paclitaxel</th>
<th>Placebo + nab-paclitaxel</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Secondary and exploratory endpoints</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigator-assessed ORR (RECIST 1.1)³</td>
<td>n=185</td>
<td>n=183</td>
</tr>
<tr>
<td>No. of responders (%)</td>
<td>109 (58.9%)</td>
<td>78 (42.6%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>(51.5, 66.1)</td>
<td>(35.4, 50.1)</td>
</tr>
<tr>
<td></td>
<td>No. of complete response (%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>19 (10.3%)</td>
<td>2 (1.1%)</td>
</tr>
<tr>
<td></td>
<td>No. of partial response (%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>90 (48.6%)</td>
<td>76 (41.5%)</td>
</tr>
<tr>
<td></td>
<td>No. of stable disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>38 (20.5%)</td>
<td>49 (26.8%)</td>
</tr>
<tr>
<td>Investigator-assessed DOR³</td>
<td>n=109</td>
<td>n=78</td>
</tr>
<tr>
<td>Median in months</td>
<td>8.5</td>
<td>5.5</td>
</tr>
<tr>
<td>95% CI</td>
<td>(7.3, 9.7)</td>
<td>(3.7, 7.1)</td>
</tr>
</tbody>
</table>

1. Based on the stratified log-rank test.
2. OS comparisons between treatment arms in patients with PD-L1 expression ≥1% were not formally tested, as per the pre-specified analysis hierarchy.
3. Per final analysis for PFS, ORR, DOR and first interim analysis for OS at clinical cut off 17th April 2018
4. Per exploratory PFS analysis at clinical cut off January 2nd 2019
5. Per final analysis for OS at clinical cut off April 14th 2020

‡ Stratified by presence of liver metastases, and by prior taxane treatment.

PFS=progression-free survival; RECIST=Response Evaluation Criteria in Solid Tumours v1.1.; CI=confidence interval; ORR=objective response rate; DOR=duration of response; OS=overall survival, NE=not estimable
Figure 18: Kaplan-Meier curve for progression free survival in patients with PD-L1 expression ≥ 1% (IMpassion130)

![Kaplan-Meier curve for progression free survival](image1)

**No. of Patients at Risk**
- Tecentriq + nab-paclitaxel: 185, 146, 104, 75, 38, 19, 10, 6, 2, 1, NE, NE
- Placebo + nab-paclitaxel: 184, 175, 150, 132, 113, 95, 85, 72, 66, 62, 54, 47, 38, 14, 7, 6, 3, 1, NE, NE

Figure 19: Kaplan-Meier curve for overall survival in patients with PD-L1 expression ≥ 1% (IMpassion130)

![Kaplan-Meier curve for overall survival](image2)

**Patients remaining at risk**
- Placebo + nab-paclitaxel: 184, 175, 150, 132, 113, 95, 85, 72, 66, 62, 54, 47, 38, 14, 7, 6, 3, 1, NE

The time to deterioration (a sustained ≥ 10-point decline from baseline score) of patient-reported global health status/health-related quality of life as measured by the EORTC QLQ-C30 was similar in each treatment group indicating that all patients maintained their baseline HRQoL for a comparable duration of time.
**Hepatocellular carcinoma**

**IMbrave150 (Y040245): Randomised phase III trial in patients with unresectable HCC who have not received prior systemic therapy, in combination with bevacizumab**

A phase III, randomised, multi-centre, international, open-label study, IMbrave150, was conducted to evaluate the efficacy and safety of azeolizumab in combination with bevacizumab, in patients with locally advanced or metastatic and/or unresectable HCC, who have not received prior systemic treatment. A total of 501 patients were randomised (2:1) to receive either azeolizumab (1 200 mg) and 15 mg/kg bw of bevacizumab every 3 weeks administered by intravenous infusion, or sorafenib 400 mg orally twice per day. Randomization was stratified by geographic region, macrovascular invasion and/or extrahepatic spread, baseline α-fetoprotein (AFP) and ECOG performance status. Patients in both arms received treatment until loss of clinical benefit, or unacceptable toxicity. Patients could discontinue either azeolizumab or bevacizumab (e.g., due to adverse events) and continue on single-agent therapy until loss of clinical benefit or unacceptable toxicity associated with the single-agent.

The study enrolled adults whose disease was not amenable to or progressed after surgical and/or locoregional therapies, were Child-Pugh A, ECOG 0/1, and who had not received prior systemic treatment. Bleeding (including fatal events) is a known adverse reaction with bevacizumab and upper gastrointestinal bleeding is a common and life threatening complication in patients with HCC. Hence, patients were required to be evaluated for the presence of varices within 6 months prior to treatment, and were excluded if they had variceal bleeding within 6 months prior to treatment, untreated or incompletely treated varices with bleeding or high risk of bleeding. For patients with active hepatitis B, HBV DNA < 500 IU/mL was required within 28 days prior to initiation of study treatment, and standard anti-HBV treatment for a minimum of 14 days prior to study entry and for the length of study.

Patients were also excluded if they had moderate or severe ascites; history of hepatic encephalopathy; known fibrolamellar HCC; sarcomatoid HCC, mixed cholangiocarcinoma and HCC; active co-infection of HBV and HCV; history of autoimmune disease; administration of a live, attenuated vaccine within 4 weeks prior to randomization; administration of systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medicinal products within 2 weeks prior to randomization; untreated or corticosteroid-dependent brain metastases. Tumour assessments were performed every 6 weeks for the first 54 weeks following Cycle 1, Day 1, then every 9 weeks thereafter.

The demographic and baseline disease characteristics of the study population were well balanced between the treatment arms. The median age was 65 years (range: 26 to 88 years) and 83% were male. The majority of patients were Asian (57%) and white (35%). 40% were from Asia (excluding Japan), while 60% were from rest of world. Approximately 75% of patients presented with macrovascular invasion and/or extrahepatic spread and 37% had a baseline AFP ≥ 400 ng/mL. Baseline ECOG performance status was 0 (62%) or 1 (38%). The primary risk factors for the development of HCC were Hepatitis B virus infection in 48% of patients, Hepatitis C virus infection in 22% of patients, and non-viral disease in 31% of patients. HCC was categorized as Barcelona Clinic Liver Cancer (BCLC) stage C in 82% of patients, stage B in 16% of patients, and stage A in 3% of patients.

The co-primary efficacy endpoints were OS and IRF-assessed PFS according to RECIST v1.1. At the time of the primary analysis, patients had a median survival follow up time of 8.6 months. The data demonstrated a statistically significant improvement in OS and PFS as assessed by IRF per RECIST v1.1 with azeolizumab + bevacizumab compared to sorafenib. A statistically significant improvement was also observed in confirmed objective response rate (ORR) by IRF per RECIST v1.1 and HCC modified RECIST (mRECIST). The key efficacy results from the primary analysis are summarized in Table 19.

A descriptive updated efficacy analysis was performed with a median survival follow up time of 15.6 months. The median OS was 19.2 months (95% CI: 17.0, 23.7) in the azeolizumab + bevacizumab
arm versus 13.4 months (95% CI: 11.4, 16.9) in the sorafenib arm with a HR of 0.66 (95% CI: 0.52, 0.85). The median PFS by IRF-assessment per RECIST v1.1 was 6.9 months (95% CI: 5.8, 8.6) in the atezolizumab + bevacizumab arm versus 4.3 months (95% CI: 4.0, 5.6) in the sorafenib arm with a HR of 0.65 (95% CI: 0.53, 0.81).

The IRF-assessed ORR per RECIST v1.1 was 29.8% (95% CI: 24.8, 35.0) in the atezolizumab + bevacizumab arm and 11.3% (95% CI: 6.9, 17.3) in the sorafenib arm. The median duration of response (DOR) by IRF-assessment per RECIST v1.1 in confirmed responders was 18.1 months (95% CI: 14.6, NE) in the atezolizumab + bevacizumab arm compared to 14.9 months (95% CI: 4.9, 17.0) in the sorafenib arm.

Kaplan-Meier curves for OS (updated analysis) and PFS (primary analysis) are presented in Figures 20 and 21, respectively.

Table 19: Summary of efficacy (1Mbrave150 primary analysis)

<table>
<thead>
<tr>
<th>Key efficacy endpoints</th>
<th>Atezolizumab + Bevacizumab</th>
<th>Sorafenib</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OS</strong></td>
<td>n=336</td>
<td>n=165</td>
</tr>
<tr>
<td>No. of deaths (%)</td>
<td>96 (28.6%)</td>
<td>65 (39.4%)</td>
</tr>
<tr>
<td>Median time to event (months)</td>
<td>NE</td>
<td>13.2</td>
</tr>
<tr>
<td>95% CI</td>
<td>(NE, NE)</td>
<td>(10.4, NE)</td>
</tr>
<tr>
<td>Stratified hazard ratio‡ (95% CI)</td>
<td>0.58 (0.42, 0.79)</td>
<td>0.59 (0.47, 0.76)</td>
</tr>
<tr>
<td>p-value¹</td>
<td>0.0006</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>6-month OS (%)</td>
<td>84.8%</td>
<td>72.3%</td>
</tr>
<tr>
<td><strong>IRF-assessed PFS, RECIST 1.1</strong></td>
<td>n=336</td>
<td>n=165</td>
</tr>
<tr>
<td>No. of events (%)</td>
<td>197 (58.6%)</td>
<td>109 (66.1%)</td>
</tr>
<tr>
<td>Median duration of PFS (months)</td>
<td>6.8</td>
<td>4.3</td>
</tr>
<tr>
<td>95% CI</td>
<td>(5.8, 8.3)</td>
<td>(4.0, 5.6)</td>
</tr>
<tr>
<td>Stratified hazard ratio‡ (95% CI)</td>
<td>0.59 (0.47, 0.76)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>p-value¹</td>
<td>&lt;0.001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>6-month PFS</td>
<td>54.5%</td>
<td>37.2%</td>
</tr>
<tr>
<td><strong>IRF-assessed ORR, RECIST 1.1</strong></td>
<td>n=326</td>
<td>n=159</td>
</tr>
<tr>
<td>No. of confirmed responders (%)</td>
<td>89 (27.3%)</td>
<td>19 (11.9%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>(22.5, 32.5)</td>
<td>(7.4, 18.0)</td>
</tr>
<tr>
<td>p-value²</td>
<td>&lt;0.0001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>No. of complete responses (%)</td>
<td>18 (5.5%)</td>
<td>0</td>
</tr>
<tr>
<td>No. of partial responses (%)</td>
<td>71 (21.8%)</td>
<td>19 (11.9%)</td>
</tr>
<tr>
<td>No. of stable disease (%)</td>
<td>151 (46.3%)</td>
<td>69 (43.4%)</td>
</tr>
<tr>
<td><strong>IRF-assessed DOR, RECIST 1.1</strong></td>
<td>n=89</td>
<td>n=19</td>
</tr>
<tr>
<td>Median in months</td>
<td>NE</td>
<td>6.3</td>
</tr>
<tr>
<td>95% CI</td>
<td>(NE, NE)</td>
<td>(4.7, NE)</td>
</tr>
<tr>
<td>Range (months)</td>
<td>(1.3+, 13.4+)</td>
<td>(1.4+, 9.1+)</td>
</tr>
<tr>
<td>Key efficacy endpoints</td>
<td>Atezolizumab + Bevacizumab</td>
<td>Sorafenib</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------------------</td>
<td>----------</td>
</tr>
<tr>
<td><strong>IRF-assessed ORR, HCC</strong></td>
<td>n=325</td>
<td>n=158</td>
</tr>
<tr>
<td>No. of confirmed responders (%)</td>
<td>108 (33.2%)</td>
<td>21 (13.3%)</td>
</tr>
<tr>
<td>95% CI</td>
<td>(28.1, 38.6)</td>
<td>(8.4, 19.6)</td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>No. of complete responses (%)</td>
<td>33 (10.2%)</td>
<td>3 (1.9%)</td>
</tr>
<tr>
<td>No. of partial responses (%)</td>
<td>75 (23.1%)</td>
<td>18 (11.4%)</td>
</tr>
<tr>
<td>No. of stable disease (%)</td>
<td>127 (39.1%)</td>
<td>66 (41.8%)</td>
</tr>
<tr>
<td><strong>IRF-assessed DOR, HCC</strong></td>
<td>n=108</td>
<td>n=21</td>
</tr>
<tr>
<td>Median in months</td>
<td>NE</td>
<td>6.3</td>
</tr>
<tr>
<td>95% CI</td>
<td>(NE, NE)</td>
<td>(4.9, NE)</td>
</tr>
<tr>
<td>Range (months)</td>
<td>(1.3+, 13.4+)</td>
<td>(1.4+, 9.1+)</td>
</tr>
</tbody>
</table>

¹ Stratified by geographic region (Asia excluding Japan vs rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. ≥400 ng/mL)

1. Based on two-sided stratified log-rank test
2. Nominal p-values based on two-sided Cochran-Mantel-Haenszel test

+ Denotes a censored value

PFS=progression-free survival; RECIST=Response Evaluation Criteria in Solid Tumors v1.1; HCC mRECIST = Modified RECIST Assessment for Hepatocellular Carcinoma; CI=confidence interval; ORR=objective response rate; DOR=duration of response; OS=overall survival; NE=not estimable
Efficacy in elderly

No overall differences in efficacy were observed between patients ≥ 65 years of age and younger patients receiving atezolizumab monotherapy. In study IMpower150, age ≥ 65 was associated with a diminished effect of atezolizumab in patients receiving atezolizumab in combination with carboplatin and paclitaxel.

In studies IMpower150, IMpower133 and IMpower110, data for patients ≥ 75 years of age are too limited to draw conclusions on this population.

Paediatric population

An early phase, multi-centre open-label study was conducted in paediatric (< 18 years, n=69) and young adult patients (18-30 years, n=18) with relapsed or progressive solid tumours as well as with Hodgkin’s and non-Hodgkin’s lymphoma, to evaluate the safety and pharmacokinetics of atezolizumab. Patients were treated with 15 mg/kg bw atezolizumab intravenously every 3 weeks (see section 5.2).
5.2 Pharmacokinetic properties

Exposure to atezolizumab increased dose proportionally over the dose range 1 mg/kg bw to 20 mg/kg bw including the fixed dose 1 200 mg administered every 3 weeks. A population analysis that included 472 patients described atezolizumab pharmacokinetics for the dose range: 1 to 20 mg/kg bw with a linear two-compartment disposition model with first-order elimination. The pharmacokinetic properties of 840 mg intravenous atezolizumab administered every 2 weeks, 1 200 mg administered every 3 weeks, and 1 680 mg administered every 4 weeks are the same; comparable total exposures are expected to be achieved with these three dosing regimens. A population pharmacokinetic analysis suggests that steady-state is obtained after 6 to 9 weeks of multiple dosing. The systemic accumulation in area under the curve, maximum concentration and trough concentration was 1.91, 1.46 and 2.75-fold, respectively.

Absorption

Atezolizumab is administered as an intravenous infusion. There have been no studies performed with other routes of administration.

Distribution

A population pharmacokinetic analysis indicates that central compartment volume of distribution is 3.28 L and volume at steady-state is 6.91 L in the typical patient.

Biotransformation

The metabolism of atezolizumab has not been directly studied. Antibodies are cleared principally by catabolism.

Elimination

A population pharmacokinetic analysis indicates that the clearance of atezolizumab is 0.200 L/day and the typical terminal elimination half-life is 27 days.

Special populations

Based on population PK and exposure-response analyses age (21-89 years), region, ethnicity, renal impairment, mild hepatic impairment, level of PD-L1 expression, or ECOG performance status have no effect on atezolizumab pharmacokinetics. Body weight, gender, positive ADA status, albumin levels and tumour burden have a statistically significant, but not clinically relevant effect on atezolizumab pharmacokinetics. No dose adjustments are recommended.

Elderly

No dedicated studies of atezolizumab have been conducted in elderly patients. The effect of age on the pharmacokinetics of atezolizumab was assessed in a population pharmacokinetic analysis. Age was not identified as a significant covariate influencing atezolizumab pharmacokinetics based on patients of age range of 21-89 years (n=472), and median of 62 years of age. No clinically important difference was observed in the pharmacokinetics of atezolizumab among patients < 65 years (n=274), patients between 65–75 years (n=152) and patients > 75 years (n=46) (see section 4.2).
**Paediatric population**

The pharmacokinetic results from one early-phase, multi-centre open-label study that was conducted in paediatric (< 18 years, n=69) and young adult patients (18-30 years, n=18), show that the clearance and volume of distribution of atezolizumab were comparable between paediatric patients receiving 15 mg/kg bw and young adult patients receiving 1 200 mg of atezolizumab every 3 weeks when normalized by body weight, with exposure trending lower in paediatric patients as body weight decreased. These differences were not associated with a decrease in atezolizumab concentrations below the therapeutic target exposure. Data for children < 2 years is limited thus no definitive conclusions can be made.

**Renal impairment**

No dedicated studies of atezolizumab have been conducted in patients with renal impairment. In the population pharmacokinetic analysis, no clinically important differences in the clearance of atezolizumab were found in patients with mild (estimated glomerular filtration rate [eGFR] 60 to 89 mL/min/1.73 m²; n=208) or, moderate (eGFR 30 to 59 mL/min/1.73 m²; n=116) renal impairment compared to patients with normal (eGFR greater than or equal to 90 mL/min/1.73 m²; n=140) renal function. Only a few patients had severe renal impairment (eGFR 15 to 29 mL/min/1.73 m²; n=8) (see section 4.2). The effect of severe renal impairment on the pharmacokinetics of atezolizumab is unknown.

**Hepatic impairment**

No dedicated studies of atezolizumab have been conducted in patients with hepatic impairment. In the population pharmacokinetic analysis, there were no clinically important differences in the clearance of atezolizumab observed in patients with mild hepatic impairment (bilirubin ≤ ULN and AST > ULN or bilirubin > 1.0 x to 1.5 x ULN and any AST) or moderate hepatic impairment (bilirubin > 1.5 to 3x ULN and any AST) in comparison to patients with normal hepatic function (bilirubin ≤ ULN and AST ≤ ULN). No data are available in patients with severe hepatic impairment (bilirubin > 3 X ULN and any AST). Hepatic impairment was defined by the National Cancer Institute-Organ Dysfunction Working Group (NCI-ODWG) criteria of hepatic dysfunction (see section 4.2). The effect of severe hepatic impairment (bilirubin > 3 x ULN and any AST) on the pharmacokinetics of atezolizumab is unknown.

### 5.3 Preclinical safety data

**Carcinogenicity**

Carcinogenicity studies have not been performed to establish the carcinogenic potential of atezolizumab.

**Mutagenicity**

Mutagenicity studies have not been performed to establish the mutagenic potential of atezolizumab. However, monoclonal antibodies are not expected to alter DNA or chromosomes.

**Fertility**

No fertility studies have been conducted with atezolizumab; however assessment of the cynomolgus monkey male and female reproductive organs was included in the chronic toxicity study. Weekly administration of atezolizumab to female monkeys at an estimated AUC approximately 6 times the AUC in patients receiving the recommended dose caused an irregular menstrual cycle pattern and a lack of newly formed corpora lutea in the ovaries which were reversible. There was no effect on the male reproductive organs.
Teratogenicity

No reproductive or teratogenicity studies in animals have been conducted with atezolizumab. Animal studies have demonstrated that inhibition of the PD-L1/PD-1 pathway can lead to immune-mediated rejection of the developing foetus resulting in foetal death. Administration of atezolizumab could cause foetal harm, including embryo-foetal lethality.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

L-histidine
Glacial acetic acid
Sucrose
Polysorbate 20
Water for injections

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

6.3 Shelf life

Unopened vial

3 years.

Diluted solution

Chemical and physical in-use stability has been demonstrated for up to 24 hours at ≤ 30 °C and for up to 30 days at 2 °C to 8 °C from the time of preparation.

From a microbiological point of view, the prepared solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 °C to 8 °C or 8 hours at ambient temperature (≤ 25 °C) unless dilution has taken place in controlled and validated aseptic conditions.

6.4 Special precautions for storage

Store in a refrigerator (2 °C – 8 °C).

Do not freeze.

Keep the vial in the outer carton in order to protect from light.

For storage conditions after dilution of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Type I glass-vial with a butyl rubber stopper and an aluminium seal with a plastic grey or aqua flip-off cap containing 14 mL or 20 mL of concentrate solution for infusion.

Pack of one vial.
6.6 Special precautions for disposal and other handling

Tecentriq does not contain any antimicrobial preservative or bacteriostatic agents and should be prepared by a healthcare professional using aseptic technique to ensure the sterility of prepared solutions. Use a sterile needle and syringe to prepare Tecentriq.

Aseptic preparation, handling and storage

Aseptic handling must be ensured when preparing the infusion. Preparation should be:

• performed under aseptic conditions by trained personnel in accordance with good practice rules especially with respect to the aseptic preparation of parenteral products.
• prepared in a laminar flow hood or biological safety cabinet using standard precautions for the safe handling of intravenous agents.
• followed by adequate storage of the prepared solution for intravenous infusion to ensure maintenance of the aseptic conditions.

Do not shake.

Instructions for dilution

For the recommended dose of 840 mg: fourteen mL of Tecentriq concentrate should be withdrawn from the vial and diluted into a polyvinyl chloride (PVC), polyolefin (PO), polyethylene (PE), or polypropylene (PP) infusion bag containing sodium chloride 9 mg/mL (0.9%) solution for injection.

For the recommended dose of 1 200 mg: twenty mL of Tecentriq concentrate should be withdrawn from the vial and diluted into a polyvinyl chloride (PVC), polyolefin (PO), polyethylene (PE) or polypropylene (PP) infusion bag containing sodium chloride 9 mg/mL (0.9%) solution for injection.

For the recommended dose of 1 680 mg: twenty-eight mL of Tecentriq concentrate should be withdrawn from two vials of Tecentriq 840 mg and diluted into a polyvinyl chloride (PVC), polyolefin (PO), polyethylene (PE), or polypropylene (PP) infusion bag containing sodium chloride 9 mg/mL (0.9%) solution for injection.

After dilution, the final concentration of the diluted solution should be between 3.2 and 16.8 mg/mL.

The bag should be gently inverted to mix the solution in order to avoid foaming. Once the infusion is prepared it should be administered immediately (see section 6.3).

Parenteral medicinal products should be inspected visually for particulates and discoloration prior to administration. If particulates or discoloration are observed, the solution should not be used.

No incompatibilities have been observed between Tecentriq and intravenous bags with product-contacting surfaces of PVC, PO, PE, or PP. In addition, no incompatibilities have been observed with in-line filter membranes composed of polyethersulfone or polysulfone, and infusion sets and other infusion aids composed of PVC, PE, polybutadiene, or polyetherurethane. The use of in-line filter membranes is optional.

Do not co-administer other medicinal products through the same infusion line.

Disposal

The release of Tecentriq in the environment should be minimised. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER

Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/17/1220/001
EU/1/17/1220/002

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 21 September 2017
Date of latest renewal: 25 April 2022

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
ANNEX II

A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORIZATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturers of the biological active substance

F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel
SWITZERLAND

and

Roche Diagnostics GmbH
Nonnenwald 2
82377 Penzberg
GERMANY

Name and address of the manufacturer responsible for batch release

Roche Pharma AG
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
GERMANY

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
• **Additional risk minimisation measures**

Prior to launch of Tecentriq in each Member State the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational programme, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority.

The educational programme is aimed at increasing awareness and providing information concerning the signs and symptoms of important identified risks of atezolizumab, including certain immune-mediated adverse reactions and infusion-related reactions, and how to manage them.

The MAH shall ensure that in each Member State where Tecentriq is marketed, all healthcare professionals and patients/carers who are expected to prescribe and use Tecentriq have access to/are provided with the following educational package:

- **Patient Card**

The **patient card** shall contain the following key messages:

- Brief introduction to atezolizumab (indication and purpose of this tool)
- Information that atezolizumab can cause serious side effects during or after treatment, that need to be treated right away
- Description of the main signs and symptoms of the following safety concerns and reminder of the importance of notifying their treating physician immediately if symptoms occur, persist or worsen:
  - Immune-Mediated Hepatitis
  - Immune-Mediated Pneumonitis
  - Immune-Mediated Colitis
  - Immune-Mediated Pancreatitis
  - Immune-Mediated Endocrinopathies (Type 1 Diabetes Mellitus, Hypothyroidism, Hyperthyroidism, Adrenal Insufficiency and Hypophysitis)
  - Immune-Mediated Neuropathies (Guillain-Barre Syndrome, Myasthenic Syndrome / Myasthenia Gravis, Facial Paresis)
  - Immune-Mediated Myelitis
  - Immune-Mediated Meningoencephalitis
  - Immune-Mediated Myocarditis
  - Immune-Mediated Nephritis
  - Immune-Mediated Myositis
  - Immune-Mediated Pericardial Disorders
  - Haemophagocytic lymphohistiocytosis
  - Infusion-Related Reactions

- Warning message for patients on the importance of consulting their doctor immediately in case they develop any of the listed signs and symptoms and on the important not attempting to treat themselves.
- Reminder to carry the Patient Card at all times and to show it to all healthcare professionals that may treat them.
- The card should also prompt to enter contact details of the physician and include a warning message for healthcare professionals treating the patient at any time, including in conditions of emergency, that the patient is using Tecentriq.
**Obligation to conduct post-authorisation measures**

The MAH shall complete, within the stated timeframe, the below measures:

<table>
<thead>
<tr>
<th>Description</th>
<th>Due date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-authorisation efficacy study (PAES): In order to further evaluate the</td>
<td>Submission of study results:</td>
</tr>
<tr>
<td>efficacy of atezolizumab for the treatment of patients with locally</td>
<td>31 December 2023</td>
</tr>
<tr>
<td>advanced or metastatic urothelial cancer, the MAH should submit the final</td>
<td></td>
</tr>
<tr>
<td>OS results of study IMvigor210.</td>
<td></td>
</tr>
</tbody>
</table>
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

Tecentriq 840 mg concentrate for solution for infusion atezolizumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each 14 mL vial of concentrate contains 840 mg atezolizumab
After dilution, the final concentration of the diluted solution should be between 3.2 and 16.8 mg/mL.

3. LIST OF EXCIPIENTS

Excipients: L-histidine, glacial acetic acid, sucrose, polysorbate 20, water for injections

4. PHARMACEUTICAL FORM AND CONTENTS

Concentrate for solution for infusion
840 mg/14 mL
1 vial

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
For intravenous use after dilution.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Do not shake the vial

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.
Do not freeze.
Keep the vial in the outer carton in order to protect from light.
<p>| 10. | SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE |
| 11. | NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER |
| Roche Registration GmbH |
| Emil-Barell-Strasse 1 |
| 79639 Grenzach-Wyhlen |
| Germany |
| 12. | MARKETING AUTHORISATION NUMBER(S) |
| EU/1/17/1220/002 |
| 13. | BATCH NUMBER |
| Batch |
| 14. | GENERAL CLASSIFICATION FOR SUPPLY |
| 15. | INSTRUCTIONS ON USE |
| 16. | INFORMATION IN BRAILLE |
| Justification for not including Braille accepted |
| 17. | UNIQUE IDENTIFIER – 2D BARCODE |
| 2D barcode carrying unique identifier included. |
| 18. | UNIQUE IDENTIFIER - HUMAN READABLE DATA |
| PC |
| SN |
| NN |</p>
<table>
<thead>
<tr>
<th>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VIAL</strong></td>
</tr>
<tr>
<td>1. <strong>NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</strong></td>
</tr>
<tr>
<td>Tecentriq 840 mg concentrate for solution for infusion</td>
</tr>
<tr>
<td>atezolizumab</td>
</tr>
<tr>
<td>Intravenous use</td>
</tr>
<tr>
<td>2. <strong>METHOD OF ADMINISTRATION</strong></td>
</tr>
<tr>
<td>For intravenous use after dilution.</td>
</tr>
<tr>
<td>3. <strong>EXPIRY DATE</strong></td>
</tr>
<tr>
<td>EXP</td>
</tr>
<tr>
<td>4. <strong>BATCH NUMBER</strong></td>
</tr>
<tr>
<td>Lot</td>
</tr>
<tr>
<td>5. <strong>CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</strong></td>
</tr>
<tr>
<td>840 mg/14 mL</td>
</tr>
<tr>
<td>6. <strong>OTHER</strong></td>
</tr>
</tbody>
</table>
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

Tecentriq 1 200 mg concentrate for solution for infusion
atezolizumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each 20 mL vial of concentrate contains 1 200 mg atezolizumab
After dilution, the final concentration of the diluted solution should be between 3.2 and 16.8 mg/mL.

3. LIST OF EXCIPIENTS

Excipients: L-histidine, glacial acetic acid, sucrose, polysorbate 20, water for injections

4. PHARMACEUTICAL FORM AND CONTENTS

Concentrate for solution for infusion
1 200 mg/20 mL
1 vial

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
For intravenous use after dilution.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Do not shake the vial

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.
Do not freeze.
Keep the vial in the outer carton in order to protect from light.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPLICABLE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/17/1220/001

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Justification for not including Braille accepted

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN
## MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

### VIAL

1. **NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION**

   Tecentriq 1 200 mg concentrate for solution for infusion
   atezolizumab
   Intravenous use

2. **METHOD OF ADMINISTRATION**

   For intravenous use after dilution.

3. **EXPIRY DATE**

   EXP

4. **BATCH NUMBER**

   Lot

5. **CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT**

   1 200 mg/20 mL

6. **OTHER**
B. PACKAGE LEAFLET
Package leaflet: Information for the patient

Tecentriq 840 mg concentrate for solution for infusion
Tecentriq 1 200 mg concentrate for solution for infusion
atezolizumab

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or nurse.
- If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Tecentriq is and what it is used for
2. What you need to know before you are given Tecentriq
3. How Tecentriq is given
4. Possible side effects
5. How to store Tecentriq
6. Contents of the pack and other information

1. What Tecentriq is and what it is used for

What Tecentriq is

Tecentriq is an anti-cancer medicine that contains the active substance atezolizumab.
- It belongs to a group of medicines called monoclonal antibodies.
- A monoclonal antibody is a type of protein designed to recognise and attach to a specific target in the body.
- This antibody can help your immune system fight your cancer.

What Tecentriq is used for

Tecentriq is used in adults to treat:
- A kind of bladder cancer, called urothelial carcinoma
- A kind of lung cancer, called non-small cell lung cancer
- A kind of lung cancer, called small cell lung cancer
- A kind of breast cancer, called triple negative breast cancer.
- A kind of liver cancer, called hepatocellular carcinoma

Patients may get Tecentriq when their cancer has spread to other parts of the body or has come back after previous treatment.

Patients may get Tecentriq when their lung cancer has not spread to other parts of the body and treatment will be given after surgery and chemotherapy. Treatment after surgery is called adjuvant therapy.

Tecentriq may be given in combination with other anticancer medicines. It is important that you also read the package leaflets for the other anticancer medicines you may be receiving. If you have any questions about these medicines, ask your doctor.
How Tecentriq works

Tecentriq works by attaching to a specific protein in your body called programmed death-ligand 1 (PD-L1). This protein suppresses the body’s immune (defence) system, thereby protecting cancer cells from being attacked by the immune cells. By attaching to the protein, Tecentriq helps your immune system to fight your cancer.

2. What you need to know before you are given Tecentriq

You must not be given Tecentriq

- if you are allergic to atezolizumab or any of the other ingredients of this medicine (listed in section 6).

If you are not sure, talk to your doctor or nurse before you are given Tecentriq.

Warnings and precautions

Talk to your doctor or nurse before you are given Tecentriq if you:

- have an auto-immune disease (a condition where the body attacks its own cells)
- have been told that your cancer has spread to your brain
- have any history of inflammation of your lungs (called pneumonitis)
- have or have had chronic viral infection of the liver, including hepatitis B (HBV) or hepatitis C (HCV)
- have human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS)
- have a significant cardiovascular (heart) disease or blood disorders or organ damage due to inadequate blood flow
- have had serious side effects because of other antibody therapies that help your immune system to fight cancer
- have been given medicines to stimulate your immune system
- have been given medicines to suppress your immune system
- have been given a live, attenuated vaccine
- have been given medicines to treat infections (antibiotics) in the past two weeks

If any of the above applies to you (or you are not sure), talk to your doctor or nurse before you are given Tecentriq.

Tecentriq may cause some side effects that you must tell your doctor about straight away. They may happen weeks or months after your last dose. Tell your doctor straight away if you notice any of the symptoms below:

- inflammation of the lung (pneumonitis): symptoms may include new or worsening cough, shortness of breath, and chest pain
- inflammation of the liver (hepatitis): symptoms may include yellowing of skin or eyes, nausea, vomiting, bleeding or bruising, dark urine, and stomach pain
- inflammation of the intestines (colitis): symptoms may include diarrhoea (watery, loose or soft stools), blood in stools, and stomach pain
- inflammation of the thyroid, adrenal glands and the pituitary gland (hypothyroidism, hyperthyroidism, adrenal insufficiency or hypophysitis): symptoms may include tiredness, weight loss, weight gain, change in mood, hair loss, constipation, dizziness, headaches, increased thirst, increased urination and changes in vision
• type 1 diabetes, including a serious, sometimes life-threatening problem due to acid in the blood produced from diabetes (diabetic ketoacidosis): symptoms may include feeling more hungry or thirsty than usual, need to urinate more often, weight loss, feeling tired or having difficulty thinking clearly, breath that smells sweet or fruity, a sweet or metallic taste in your mouth, or a different odour to your urine or sweat, nausea or vomiting, stomach pain, and deep or fast breathing
• inflammation of the brain (encephalitis) or inflammation of the membrane around the spinal cord and brain (meningitis): symptoms may include neck stiffness, headache, fever, chills, vomiting, eye sensitivity to light, confusion and sleepiness
• inflammation or problems of the nerves (neuropathy): symptoms may include weakness in the arm and leg muscles, or face muscles, double vision, difficulties with speech and chewing, numbness, and tingling in hands and feet
• inflammation of the spinal cord (myelitis): symptoms may include pain, abnormal sensations such as numbness, tingling, coldness or burning, weakness in the arms or legs, and bladder and bowel problems
• inflammation of the pancreas (pancreatitis): symptoms may include abdominal pain, nausea and vomiting
• inflammation of the heart muscle (myocarditis): symptoms may include shortness of breath, decreased exercise tolerance, feeling tired, chest pain, swelling of the ankles or legs, irregular heartbeat, and fainting
• inflammation of the kidneys (nephritis): symptoms may include changes in urine output and colour, pain in pelvis, and swelling of the body and may lead to failure of the kidneys
• inflammation of the muscles (myositis): symptoms may include muscle weakness, fatigue after walking or standing, tripping or falling, and trouble swallowing or breathing
• severe reactions associated with infusion (events occurring during the infusion or within one day of the infusion): may include fever, chills, shortness of breath and flushing
• severe skin reactions (SCARs); which may include rash, itching, skin blistering, peeling or sores, and/or ulcers in the mouth or in lining of the nose, throat or genital area
• inflammation of the heart sac with build-up of fluid in the sac (in some cases) (pericardial disorders): symptoms are similar to those of myocarditis and may include chest pain (usually over the front of the chest, sharp, and worsened by deep breathing and better when you sit up and lean forward in case of inflammation of the heart sac), cough, irregular heartbeat, swelling of the ankles, legs or abdomen, shortness of breath, fatigue, and fainting
• a condition where the immune system makes too many infection-fighting cells called histiocytes and lymphocytes that may cause various symptoms (haemophagocytic lymphohistiocytosis): symptoms may include enlarged liver and/or spleen, skin rash, lymph node enlargement, breathing problems, easy bruising, kidney abnormalities, and heart problems

If you notice any of the symptoms above, tell your doctor straight away.

Do not try to treat yourself with other medicines. Your doctor may:
• Give you other medicines to prevent complications and reduce symptoms.
• Delay giving your next dose of Tecentriq.
• Stop your treatment with Tecentriq.

Tests and checks

Before your treatment, your doctor will check your general health. You will also have blood tests during your treatment.

Children and adolescents

This medicine should not be given to children or adolescents below 18 years of age. This is because the safety and efficacy of Tecentriq have not been established in this age group.

Other medicines and Tecentriq
Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription, including herbal medicines.

**Pregnancy and contraception**

- If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
- You will not be given Tecentriq if you are pregnant unless your doctor considers it necessary. This is because the effect of Tecentriq in pregnant women is not known - it is possible that it could harm your unborn baby.
- If you could become pregnant, you must use effective contraception:
  - while you are being treated with Tecentriq and
  - for 5 months after the last dose.
- If you become pregnant while you are being treated with Tecentriq tell your doctor.

**Breast-feeding**

It is not known if Tecentriq gets into breast milk. Ask your doctor if you should stop breast-feeding or if you should stop treatment with Tecentriq.

**Driving and using machines**

Tecentriq has minor influence on your ability to drive and use machines. If you feel tired, do not drive or use machines until you feel better.

3. **How Tecentriq is given**

You will be given Tecentriq by a doctor experienced in cancer treatment in a hospital or clinic.

**How much Tecentriq is given**

The recommended dose is either:

- 840 milligrams (mg) every two weeks, or
- 1 200 milligrams (mg) every three weeks, or
- 1 680 milligrams (mg) every four weeks.

**How Tecentriq is given**

Tecentriq is given as a drip into a vein (an intravenous infusion).

Your first infusion will be given over 60 minutes.

- Your doctor will monitor you carefully during the first infusion.
- If you do not have an infusion reaction during the first infusion, the next infusions will be given to you over a period of 30 minutes.

**How long treatment lasts**

Your doctor will keep giving you Tecentriq until you no longer benefit from it. However, it may be stopped if the side effects become too much of a problem.
If you miss a dose of Tecentriq

If you miss an appointment, make another one straight away. For the treatment to be fully effective, it is very important to keep having the infusions.

If you stop receiving Tecentriq

Do not stop treatment with Tecentriq unless you have discussed this with your doctor. This is because stopping treatment may stop the effect of the medicine.

If you have any further questions on the use of this medicine, ask your doctor or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor straight away if you notice any of the side effects below or if they get worse. They may happen weeks or months after your last dose. Do not try to treat yourself with other medicines.

Tecentriq used alone

The following side effects have been reported in clinical trials with Tecentriq used alone:

Very common: may affect more than 1 in 10 people
- fever
- nausea
- vomiting
- feeling very tired with no energy (fatigue)
- lack of energy
- itching of the skin
- diarrhoea
- joint pain
- rash
- loss of appetite
- shortness of breath
- urinary tract infection
- back pain
- cough
- headache

Common: may affect up to 1 in 10 people
- inflammation of the lungs (pneumonitis)
- low oxygen levels, which may cause shortness of breath as a consequence of inflamed lungs (hypoxia)
- stomach pain
- pain in the muscles and bones
- inflammation of the liver
- elevated liver enzymes (shown in tests), which may be a sign of an inflamed liver
- difficulty swallowing
- blood tests showing low levels of potassium (hypokalaemia) or sodium (hyponatremia)
- low blood pressure (hypotension)
- underactive thyroid gland (hypothyroidism)
- allergic reaction (infusion-related reaction, hypersensitivity or anaphylaxis)
- flu-like illness
• chills
• inflammation of the intestines
• low platelet count, which may make you more likely to bruise or bleed
• high blood sugar
• common cold (nasopharyngitis)
• mouth and throat pain, or dry mouth
• dry skin
• abnormal kidney test (possible kidney damage)
• overactive thyroid gland (hyperthyroidism)
• inflammation of the heart sac with build-up of fluid in the sac (in some cases) (pericardial disorders)

Uncommon: may affect up to 1 in 100 people
• inflammation of the pancreas
• numbness or paralysis, which may be signs of Guillain-Barré syndrome
• inflammation of the membrane around the spinal cord and brain
• low levels of adrenal hormones
• type 1 diabetes (including diabetic ketoacidosis)
• inflammation of muscles (myositis)
• red, dry, scaly patches of thickened skin (psoriasis)
• inflammation of the kidneys
• inflammation of the heart sac with build-up of fluid in the sac (in some cases) (pericardial disorders)

Rare: may affect up to 1 in 1,000 people
• inflammation of the heart muscle
• myasthenia gravis, an illness that can cause muscle weakness
• inflammation of the pituitary gland situated at the base of the brain
• inflammation of the eye (uveitis)
• haemophagocytic lymphohistiocytosis, a condition where the immune system makes too many infection-fighting cells called histiocytes and lymphocytes that may cause various symptoms
• inflammation of the spinal cord (myelitis)
• weakness of facial nerves and muscles (facial paresis)

Other side effects that have been reported (not known: cannot be estimated from the available data):
• inflammation of the bladder; signs and symptoms may include frequent and/or painful urination, urge to pass urine, blood in urine, pain or pressure in lower abdomen

Tecentriq used in combination with anticancer medicines

The following side effects have been reported in clinical trials when Tecentriq is given in combination with anticancer medicines:

Very common: may affect more than 1 in 10 people
• low number of red blood cells, which can cause tiredness and shortness of breath
• low white blood cell count with and without fever, which can increase the risk of infection (neutropenia, leukopenia)
• low platelet count, which may make you more likely to bruise or bleed (thrombocytopenia)
• constipation
• nerve damage resulting in possible numbness, pain, and/or loss of motor function (peripheral neuropathy)
• underactive thyroid gland (hypothyroidism)
• loss of appetite
• shortness of breath
• diarrhoea
• nausea
• itching of the skin
• rash
• joint pain
• feeling very tired (fatigue)
• fever
• headache
• cough
• pain in the muscles and bones
• vomiting
• back pain
• lack of energy
• infection of the lung
• common cold (nasopharyngitis)
• hair loss
• high blood pressure (hypertension)
• swelling in arms or legs

Common: may affect up to 1 in 10 people
• blood tests showing low levels of potassium (hypokalaemia) or sodium (hyponatremia)
• inflammation of the mouth or lips
• hoarse voice (dysphonia)
• low levels of magnesium (hypomagnesaemia), which can cause weakness and muscle cramping, numbness and pain in the arms and legs
• protein in urine (proteinuria)
• fainting
• elevated liver enzymes (shown in tests), which may be a sign of an inflamed liver
• changes to sense of taste (dysgeusia)
• decreased number of lymphocyte (a type of white blood cells), which is associated with an increased risk of infection
• abnormal kidney test (possible kidney damage)
• overactive thyroid gland (hyperthyroidism)
• dizziness
• infusion-related reactions
• severe infection in the blood (sepsis)

Uncommon: may affect up to 1 in 100 people
• red, dry, scaly patches of thickened skin (psoriasis)
• itching, skin blistering, peeling or sores, and/or ulcers in the mouth or in lining of nose, throat, or genital area which can be severe (severe skin reactions)
• inflammation of the heart sac with build-up of fluid in the sac (in some cases) (pericardial disorders)

Rare: may affect up to 1 in 1,000 people
• haemophagocytic lymphohistiocytosis, a condition where the immune system makes too many infection-fighting cells called histiocytes and lymphocytes that may cause various symptoms
• weakness of facial nerves and muscles (facial paresis)

If you notice any of the side effects above or if they get worse, tell your doctor straight away.

Reporting of side effects

If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in
Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Tecentriq

Tecentriq will be stored by the healthcare professionals at the hospital or clinic. The storage details are as follows:

- Do not use this medicine after the expiry date which is stated on the carton and the vial label after EXP. The expiry date refers to the last day of that month.
- Store in a refrigerator (2 °C - 8 °C). Do not freeze.
- Keep the vial in the outer carton in order to protect from light.
- The diluted solution should not be kept more than 24 hours at 2 °C to 8 °C or 8 hours at ambient temperature (≤ 25 °C), unless dilution has taken place in controlled and validated aseptic conditions.
- Do not use if this medicine is cloudy, discoloured or contains particles.

Do not throw away any medicines via wastewater or household waste. Your healthcare professional will throw away any medicines that are no longer being used. These measures will help to protect the environment.

6. Contents of the pack and other information

What Tecentriq contains

- The active substance is atezolizumab. Each mL contains 60 mg of atezolizumab. Each 14 mL vial contains 840 mg of atezolizumab. Each 20 mL vial contains 1200 mg of atezolizumab.
- After dilution, the final concentration of the diluted solution should be between 3.2 and 16.8 mg/mL.
- The other ingredients are L-histidine, glacial acetic acid, sucrose, polysorbate 20 and water for injections.

What Tecentriq looks like and contents of the pack

Tecentriq is a concentrate for solution for infusion. It is a clear, colourless to slightly yellowish liquid.

Tecentriq is available in a pack containing 1 glass vial.

Marketing Authorisation Holder

Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany

Manufacturer

Roche Pharma AG
Emil-Barell-Strasse 1
D-79639
Grenzach-Wyhlen
Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**België/Belgique/Belgien**
N.V. Roche S.A.
Tél/Tel: +32 (0) 2 525 82 11

**България**
Рош България ЕООД
Тел: +359 2 818 44 44

**Lietuva**
UAB “Roche Lietuva”
Tel: +370 5 2546799

**Luxembourg/Luxemburg**
(Voir/siehe Belgique/Belgien)

**Česká republika**
Roche s. r. O.
Tel: +420 - 2 20382111

**Danmark**
Roche Pharmaceuticals A/S
Tlf: +45 - 36 39 99 99

**Magyarország**
Roche (Magyarország) Kft.
Tel: +36 - 1 279 4500

**Malta**
(See Ireland)

**Deutschland**
Roche Pharma AG
Tel: +49 (0) 7624 140

**Nederland**
Roche Nederland B.V.
Tel: +31 (0) 348 438050

**Eesti**
Roche Eesti OÜ
Tel: +372 - 6 177 380

**Norge**
Roche Norge AS
Tlf: +47 - 22 78 90 00

**Österreich**
Roche Austria GmbH
Tel: +43 (0) 1 27739

**España**
Roche Farma S.A.
Tel: +34 - 91 324 81 00

**Polska**
Roche Polska Sp.z o.o.
Tel: +48 - 22 345 18 88

**France**
Roche
Tél: +33 (0) 1 47 61 40 00

**Portugal**
Roche Farmacêutica Química, Lda
Tel: +351 - 21 425 70 00

**Hrvatska**
Roche d.o.o.
Tel: +385 1 4722 333

**România**
Roche România S.R.L.
Tel: +40 21 206 47 01

**Ireland**
Roche Products (Ireland) Ltd.
Tel: +353 (0) 1 469 0700

**Slovenija**
Roche farmacevtska družba d.o.o.
Tel: +386 - 1 360 26 00
Ísland
Roche Pharmaceuticals A/S
c/o Icepharma hf
Sími: +354 540 8000

Slovenská republika
Roche Slovensko, s.r.o.
Tel: +421 - 2 52638201

Italia
Roche S.p.A.
Tel: +39 - 039 2471

Suomi/Finland
Roche Oy
Puh/Tel: +358 (0) 10 554 500

Κύπρος
Γ.Α.Σταμάτης & Σια Λτδ.
Τηλ: +357 - 22 76 62 76

Sverige
Roche AB
Tel: +46 (0) 8 726 1200

Latvija
Roche Latvija SIA
Tel: +371 - 6 7039831

United Kingdom (Northern Ireland)
Roche Products (Ireland) Ltd.
Tel: +44 (0) 1707 366000

This leaflet was last revised in

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu
The following information is intended for healthcare professionals only:

Instructions for dilution

For the recommended dose of 840 mg: fourteen mL of Tecentriq concentrate should be withdrawn from the vial and diluted into a polyvinyl chloride (PVC), polyolefin (PO), polyethylene (PE), or polypropylene (PP) infusion bag containing sodium chloride 9 mg/mL (0.9%) solution for injection.

For the recommended dose of 1 200 mg: twenty mL of Tecentriq concentrate should be withdrawn from the vial and diluted into a polyvinyl chloride (PVC), polyolefin (PO), polyethylene (PE), or polypropylene (PP) infusion bag containing sodium chloride 9 mg/mL (0.9%) solution for injection.

For the recommended dose of 1 680 mg: twenty-eight mL of Tecentriq concentrate should be withdrawn from two vials of Tecentriq 840 mg and diluted into a polyvinyl chloride (PVC), polyolefin (PO), polyethylene (PE), or polypropylene (PP) infusion bag containing sodium chloride 9 mg/mL (0.9%) solution for injection.

After dilution, the final concentration of the diluted solution should be between 3.2 and 16.8 mg/mL. The bag should be gently inverted to mix the solution in order to avoid foaming. Once the infusion is prepared it should be administered immediately.

Parenteral medicinal products should be inspected visually for particulates and discoloration prior to administration. If particulates or discoloration are observed, the solution should not be used.

No incompatibilities have been observed between Tecentriq and intravenous bags with product-contacting surfaces of PVC, PO, PE, or PP. In addition, no incompatibilities have been observed with in-line filter membranes composed of polyethersulfone or polysulfone, and infusion sets and other infusion aids composed of PVC, PE, polybutadiene, or polyetherurethane. The use of in-line filter membranes is optional.

Diluted solution

Chemical and physical in-use stability has been demonstrated for up to 24 hours at ≤ 30 °C and for up to 30 days at 2 °C to 8 °C from the time of preparation.

From a microbiological point of view, the prepared solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 °C to 8 °C or 8 hours at ambient temperature (≤ 25 °C), unless dilution has taken place in controlled and validated aseptic conditions.

Method of administration

Tecentriq is for intravenous use. The infusions must not be administered as an intravenous push or bolus.

The initial dose of Tecentriq must be administered over 60 minutes. If the first infusion is well tolerated all subsequent infusions may be administered over 30 minutes.

Do not co-administer other medicinal products through the same infusion line.

Disposal

The release of Tecentriq in the environment should be minimised. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.